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Abstract
The same novel properties of engineered nanoparticles that make them attractive
may also present unique exposure risks. But, the traditional physiologically-based
pharmacokinetic (PBPK) modeling assumption of instantaneous equilibration likely
does not apply to nanoparticles. This simulation-based research begins with devel-
opment of a model that includes diﬀusion, active transport, and carrier mediated
transport. An eigenvalue analysis methodology was developed to examine model be-
havior to focus future research. Simulations using the physico-chemical properties of
size, shape, surface coating, and surface charge were performed and an equation was
determined which estimates area under the curve for arterial blood concentration,
which is a surrogate of nanoparticle dose.
Results show that the cellular transport processes modeled in this research greatly
aﬀect the biokinetics of nanoparticles. Evidence suggests that the equation used to
estimate area under the curve for arterial blood concentration can be written in terms
of nanoparticle size only. The new paradigm established by this research leverages
traditional in vitro, in vivo, and PBPK modeling, but includes area under the curve to
bridge animal testing results to humans. This new paradigm allows toxicologists and
policymakers to then assess risk to a given exposure and assist in setting appropriate
exposure limits for nanoparticles.
This research provides critical understanding of nanoparticle biokinetics and al-
lows estimation of total exposure at any toxicological endpoint in the body. This eﬀort
is a signiﬁcant contribution as it highlights future research needs and demonstrates
how modeling can be used as a tool to advance nanoparticle risk assessment.
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PROVIDING A THEORETICAL BASIS FOR NANOTOXICITY RISK
ANALYSIS DEPARTING FROM TRADITIONAL PHYSIOLOGICALLY-BASED
PHARMACOKINETIC (PBPK) MODELING
I. Introduction
1.1 Overview
Nanotechnology is a growing ﬁeld of science and manufacturing in which nanopar-
ticles are exploited for their novel properties [28, 53, 1, 2, 3, 5]. Engineered nanopar-
ticles, which are particulate structures less than 100 nanometers (nm) in size, lead to
intriguing possibilities in consumer products, materials, and diagnostic/therapeutic
medicine. Without a doubt, the rapid growth in the use of nanotechnology is likely
to provide signiﬁcant beneﬁts to society, but increasing concern regarding potential
adverse health eﬀects of nanoparticles has driven considerable research worldwide.
In response to such concerns, the Clinton administration started the National Nan-
otechnology Initiative (NNI), designed to coordinate nanotechnology-related research
across federal agencies and to create a strategic research plan to address the envi-
ronmental and health implications of nanotechnology. Research funding has nearly
tripled from $464 million in 2001 to an estimated $1.301 billion in 2006, largely due
to stimulus from NNI [46]. An estimated $29 billion in sales of nanotechnology prod-
ucts was projected for 2008, with the worldwide nanotechnology industry growing to
an estimated $1 trillion by 2015 [60]. With respect to the Department of Defense,
the Air Force Research Laboratory (AFRL) has nanotechnology research and design
emphasis in the following areas: energy, information, bio/nano, sensors, materials,
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structures, and propulsion. Projects include: improving battery life, determining
toxicity and biological interactions, nanocomposite materials, self-healing nanomate-
rials, and nanocoatings for fuel components [81].
This dissertation looks at existing literature, in order to develop a pharmacoki-
netic model representing theorized transport processes which explain nanoparticle
kinetics and distribution within the body. Due to their small size, nanoparticles
can pass between or through cells [54], allowing translocation to parts of the body
not typically reachable by larger particles. The traditional pharmacokinetic mod-
eling assumption of instantaneous equilibration, in which there is an instantaneous
equilibration between blood and tissue within the capillary beds of the circulatory
system, does not appear to apply to engineered nanoparticles, therefore warranting
more rigorous modeling of the nanoparticle transport by including physico-chemical
properties of engineered particles. Similarly, toxicological dose-response research on
chemicals often relies on a metric of mass to represent dose, whereas physico-chemical
properties must also be considered when dealing with nanoparticles.
1.2 Research Questions
Instantaneous equilibration between blood and tissue within the capillary beds
of the circulatory system is a commonly used assumption for chemical models and
presumably is not a good assumption for nanoparticle modeling. Instead, there are
several known transport processes that apply to biological systems, many of which
have not been extensively modeled in PBPK models. However, it is not known for
certain which of these transport processes apply to nanoparticles. Therefore, the
research questions posed as the basis for this dissertation are:
1. For nanoparticle PBPK modeling, what are the implications of these diﬀerent
processes on tissue concentrations, as compared to an assumption of instanta-
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neous equilibration?
2. How can these implications guide the direction of nanotoxicity research, partic-
ularly in determining parameter values for transport processes elucidated to be
important?
3. How will these ﬁndings suggest a possible new paradigm for nanoparticle risk
analysis, particularly in the area of dose-response assessment?
These three research questions are used as the basis for the dissertation and the
three phases of research (i.e., Model Formulation, Inclusion of Physico-Chemical Prop-
erties, and Deﬁning a New Paradigm for Risk Analysis) are speciﬁcally designed to
provide answers to these questions. These answers are presented in Section 5.1 on
page 121.
1.3 Assumptions
A goal of this research is to create a fully-functional, physiologically-accurate
nanoparticle PBPK model which explores the impact of cellular transport processes
on overall system behavior. Further goals include guiding future research and helping
deﬁne a more appropriate approach to risk analysis for nanomaterials.
It is acknowledged here, and in the literature, that translocation rates and details
on accumulation and retention in critical target sites are largely unknown [54]. With
the considerable lack of data regarding nanoparticle biokinetics, several assumptions
must ﬁrst be made in order to enable this dissertation research. Note that a further
discussion of assumptions is located in Appendix A on page 125. The key assumptions
are:
1. Physiological parameters were estimated as best as possible, using the method-
ology to be described later in Section 2.3.1 on page 26. For example, parameters
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such as organ volumes, blood ﬂow rates, respiration rates, etc., are fairly well
published, but other parameters such as the fraction of organ volume classiﬁed
as extracellular or intracellular are not.
2. Model is not calibrated against in vitro or in vivo data. A motivating factor
driving this research is the fact that such data are limited and, therefore, a
goal of this dissertation is to encourage research toward quantifying unknown
parameters governing nanoparticle biokinetics.
3. Initial assumption is that the same transport processes apply to all organs and
mathematical representations of the transport processes are identical across the
organs. However, the second phase of research explores the eﬀects of nanoparti-
cle physico-chemical properties and these organ-speciﬁc characteristics are used
to modify the mathematical representations.
4. High concentrations do not necessarily equate to adverse eﬀects. This research
does not address the toxic eﬀects of speciﬁc nanomaterials as that is the focus
of in vitro research.
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II. Literature Review
2.1 Nanotoxicology
The primary motivation behind this proposed dissertation research is founded
on the widely accepted belief that nanoparticles present unique exposure risks as
compared to larger sized particles of the same material. Although the toxicology of a
base material may be thoroughly deﬁned, the toxicity of the same material when in
nano size may be very diﬀerent [57]. In general, it is believed that physico-chemical
properties of nanoparticles, such as size, shape, surface charge, solubility, surface
area, etc., inﬂuence both the disposition of particles in the lungs and the biological
responses [47].
For example, although larger particles of gold are relatively inert, nano-sized par-
ticles of gold can elicit a biological response [54] and can be fairly toxic to tissue.
Greater surface area per unit mass renders nanoparticles more active biologically
than larger-sized particles of the same chemistry [57]. This is because smaller par-
ticles occupy less volume, resulting in more particles in a given volume and greater
surface area per unit mass [54]. Smaller particles have a greater fraction of atoms at
the surface, leading to increased surface reactivity [31]. In addition, surface modiﬁ-
cations of nanoparticles can signiﬁcantly alter their properties, with distribution of
nanoparticles strongly depends on surface characteristics [57]. It is important to note
that agglomeration and aggregation may occur during handling of bulk nanomateri-
als, thus increasing the eﬀective size of the material and thereby potentially aﬀecting
the nanotoxicity.
Although the toxicological eﬀects of engineered nanoparticles on the human body
are not fully understood, existing research on combustion-derived nanoparticles oﬀers
considerable insight into possible eﬀects. This includes generation of free radicals and
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oxidative stress, leading to inﬂammation and possible cardiovascular disease, asthma,
chronic obstructive pulmonary disease (COPD), scarring, and cancer [77]. Fibrosis in
the alveolar interstitium is also possible [69]. Figure 1 shows the potential exposure
pathways and health consequences of nanoparticle exposures, due to inhalational
exposure.
Figure 1. Potential pathways, consequences of nanoparticle exposures (from
Oberdo¨rster, et al.) [58]
Nanoparticles also present additional exposure and uptake pathways that present
challenges in health risk assessments. For example, once nanoparticles are deposited
in the alveolar region (i.e., deep lung), they appear to be able to translocate out of
the lungs and reach other target organs in the body [57]. Speciﬁcally, nanoparticles
penetrate the alveolar epithelial lining of the deep lung and subsequently enter the
lung interstitium to a greater extent than an equal mass of larger particles [47]. Also,
nanoparticles have a propensity to cross cell barriers, enter cells, and interact with
subcellular structures [58], thus presenting new interactions not necessarily seen for
larger particles. The ability to reach new regions, unhindered by natural blocking
mechanisms, makes nanoparticles attractive in medical applications [31], but these
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same abilities present challenges when trying to assess risk of exposure to nanomate-
rials in the occupational setting.
Due to their size, very low mass concentrations of nanoparticles in air can represent
extremely high particle number concentrations. Extraordinarily high number concen-
trations (number of particles per given mass) can be of toxicological signiﬁcance as
evidence suggests that high number concentrations inhaled can overwhelm the clear-
ance mechanism of phagocytosis in the deep lung, thus allowing more nanoparticles
to translocate out of the lungs and reach various toxic endpoints in the human body
[11, 79]. This overloading phenomenon and potential systemic translocation present
signiﬁcant challenges in occupational risk exposure, whereas larger particles tend to
be cleared from or remain sequestered in the deep lungs. Note also that the rel-
atively low mass associated with nanoparticles suggests that number concentration
(i.e., number of particles per unit volume) is a more relevant descriptor of exposure
than traditional mass concentration. Besides number concentration, the surface area
of a nanoparticle may be a better predictor (than mass), due to the higher biologic
activity associated with higher surface area.
In general, the lack of toxicological data presents a challenge in performing risk
assessments for exposures to nanoparticles. Most nanotoxicology research to date has
been performed in vitro, i.e., in cell cultures. The challenge, therefore, is extrapolating
these in vitro ﬁndings to the in vivo environment (i.e., inside the living organism),
especially to the human scale. The incomplete data set, and sometimes inconclusive
results, have led to the inability to set nanoparticle-speciﬁc exposure limits.
2.1.1 Absorption, Distribution, Metabolism, Excretion (ADME).
Very few pharmacokinetic studies, which detail the rate and extent of absorption,
distribution, metabolism, and excretion (ADME), have been performed on nanoma-
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terials. Figure 2 shows conﬁrmed and potential exposure routes, including inhalation,
ingestion, and dermal.
Figure 2. Conﬁrmed and potential routes for nanoparticle exposures (from Oberdo¨rster
et al. and Environmental Health Perspectives) [57]
The lack of studies has left many unanswered questions, including one posed
by Riviere and Tran in their article on pharmacokinetics of nanomaterials which
asks whether nanoparticle movement follows traditional thinking of diﬀusion as the
primary mode of chemical movement [64]. A primary objective of this dissertation
research is to present a pharmacokinetic model, which begins to explore ADME by
including cellular transport processes not typically included in such models.
2.1.1.1 Absorption.
Absorption is the generic term used to describe how toxicants initially enter the
mammalian system by crossing tissue membranes and entering the bloodstream at
several sites including the gastrointestinal tract, lungs, and skin [34]. In most oc-
cupational settings, the primary route of exposure to nanoparticles is likely to be
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inhalation, and therefore the primary site of absorption is the lungs. Ingestion of
nanoparticles is possible from eating or drinking contaminated items and from clear-
ance due to phagocytosis with subsequent swallowing.
Dermal absorption of nanoparticles is theorized as being possible, although its
likelihood is debatable. There is conﬂicting evidence on whether nanoparticles eﬀec-
tively penetrate the skin and can enter circulation. The skin provides a large surface
area, approximately 1.5 m2 for humans, and in theory, presents a large potential route
of exposure. It is comprised of the epidermis, dermis, and subcutaneous layers. The
outer portion of the epidermis, called the stratum corneum, forms a 10 휇m thick ker-
atinized layer of dead cells which is normally considered a fairly tight barrier against
nanoparticle penetration.
Tinkle, et al., concluded that risk of dermal translocation is minimal to non-
existent, except in the event of broken skin and where skin ﬂexing occurs [75]. Pen-
etration at the hair follicles is another possible pathway [8]. Evidence suggests that
if dermal penetration does occur, such as through compromised skin, nanoparticles
appear to be able to translocate via lymphatic uptake to regional lymph nodes, with
subsequent entrance into the blood circulation system.
For inhaled particles, larger particles tend to be deposited further up in the res-
piratory tract, due to gravitational settling, impaction, and interception. The nasal
and upper airway regions present a fairly robust barrier with epithelial tissue covered
in a layer of thick mucus. Particles smaller than 10 휇m can reach the gas exchange
surfaces (alveoli), where Brownian motion leads to deposition [8]. Very small particles
(< 1 휇m) can be exhaled, thereby reducing deep lung deposition [87].
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2.1.1.2 Distribution.
After the toxicant is absorbed into the blood, distribution to tissues throughout
the body normally occurs fairly rapidly. Rate of distribution is determined primarily
by blood ﬂow and rate of diﬀusion out of capillaries and into organs and tissue [34].
Distribution to several organs may occur, via multiple means of translocation (e.g.,
circulatory system, lymphatic system, neurons). Nanoparticles may have unique dis-
tribution properties as research indicates that regardless of exposure route, the body
distribution of nanoparticles is highly dependent on the surface characteristics and
size of the particles [27].
2.1.1.3 Metabolism.
Although metabolism (biotransformation) commonly occurs for exposures to for-
eign chemicals (xenobiotics), there is no evidence in literature of biotransformation
of nanoparticles. Therefore, this dissertation research will not cover metabolism.
2.1.1.4 Excretion.
Several clearance mechanisms exist to eliminate toxicants, including nanoparticles,
from the body. Exhalation, urine, and feces are the primary modes of excretion.
Exhalation of nanoparticles occurs as not all inhaled particles are deposited within
the respiratory tract. Urine is produced during the ﬁltration of blood as it travels
through the kidney. Nanoparticles can also travel through the gastrointestinal (GI)
tract following digestion to exit the body as feces. In addition, the liver can pass
foreign materials into bile which exits to the GI tract for possible excretion with feces.
The liver can eﬀectively remove foreign materials from both systemic circulation and
portal circulation (blood ﬂow from the GI tract). Bodily ﬂuids, such as sweat, saliva,
tears, and breast milk are other possible means of secreting toxicants [34], but are
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not included in this dissertation.
2.1.2 Organs of Concern.
2.1.2.1 Respiratory Tract.
Research indicates signiﬁcant diﬀerences exist between the fate of nano-sized parti-
cles versus larger particles, with respect to deposition and clearance in the respiratory
tract. In general, smaller particles travel deeper into the respiratory tract where they
can undergo deposition. For example, particles of diameter 1 휇m and smaller, which
includes nanoparticles, can reach the deep lung where alveolar sacs reside [34].
The primary means of deposition of nanoparticles in the respiratory tract is Brow-
nian motion (diﬀusion), which dominates at smaller diameters. Nanoparticles typ-
ically behave much like gas molecules, moving randomly by Brownian motion [69].
Inertial impaction, gravitational settling, and interception do not contribute signiﬁ-
cantly to nanoparticle deposition, due to the small particle mass and momentum. It
should be noted that these statements pertain to singlet particles (monodisperse) and
the existence of agglomerates and aggregates will lead to disposition following larger
particle size behavior. Note also that electrostatic precipitation will occur only with
nanoparticles carrying signiﬁcant electrical charge relative to its surroundings [57].
Evidence suggests that a high fraction of inhaled nanoparticles can deposit in
the tracheobronchial and pulmonary regions of the lung, with the deposition being
greater than that for inhalation of equivalent amounts of coarse or ﬁne particles.
Also, high deposition in one region of the respiratory tract does not necessarily imply
a corresponding high dose.
Regarding the fate of nanoparticles in the respiratory tract, several clearance
mechanisms are possible. First, a portion of inhaled particles may be exhaled. Second,
deposited particles can be captured in the mucus which lines the conducting zone of
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the respiratory tract. Particles captured in the mucus layer of the airways can be
cleared via the mucociliary escalator, where mucus is moved along at a velocity of
1-2 cm/min by cilia projecting from the top of epithelial cells [16]. Third, particles
reaching the deep lung (alveolar space) can be phagocytized and subsequently cleared
by the mucociliary escalator.
Additionally, particles can remain sequestered in the lungs with some crossing
the lung epithelium into the interstitial region. The alveolar wall (epithelium) is
only one cell thick, leaving only a thin barrier between inhaled nanoparticles and
the bloodstream, thus presenting a pathway into the interstitial region for nano-sized
particles. Results of several studies have shown that nanoparticles deposited in the
respiratory tract gain access to epithelial cells and interstitial ﬂuid [57]. Known as
‘interstitial translocation’, it is caused by nanoparticles escaping phagocytosis due
to either their small size [57] or overloading of the alveolar macrophage capacity to
phagocytize particles.
Several studies have demonstrated this translocation capability of nanoparticles,
including a study using ultraﬁne particles of polytetraﬂuoroethylene (PTFE) which
showed that shortly after a 15-minute exposure, the ﬂuorine-containing particles were
found in interstitial sites of the conducting airways [57]. Once in the interstitium,
translocation away from the respiratory tract and into the circulatory or lymphatic
systems is possible [8]. Oberdo¨rster et al., demonstrated how inhaled 13C particles
(25 nm) were rapidly cleared from rat lungs within 24 hours and translocated to other
organs, including the liver and spleen [56, 47].
Note that it is likely that alveolar translocation is dependent on particle size
and surface chemistry [57]. It is yet to be determined the exact mechanisms by
which ultraﬁnes penetrate cellular membranes. Therefore, the exact mechanism of
penetration through pulmonary tissue leading into capillaries is undetermined.
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Many chemical PBPK models use a simplifying assumption for the lungs in which
the toxicant in the alveolar space is assumed to equilibrate very rapidly with capillary
blood. This instantaneous equilibration is represented using a partition coeﬃcient.
For nanoparticles, it is likely more appropriate to expand the model to include depo-
sition, macrophage/mucociliary escalator clearance, and translocation away from the
interstitium.
2.1.2.2 Gastrointestinal Tract.
The gastrointestinal (GI) tract presents a potential exposure pathway, following
ingestion of food or water containing nanoparticles, or due to clearance of inhaled
nanoparticles from the respiratory tract by the mucociliary escalator. Several studies
conclude that nanoparticles can be eﬃciently absorbed through the GI tract, with
translocation into the lymphatic and circulatory systems [31]. For unintentional ex-
posures, it is believed that most nanoparticles simply pass thru the gastrointestinal
tract and are rapidly eliminated [57].
If not rapidly eliminated, products of digestion can be absorbed into blood capil-
laries. Absorption is most likely due to passive diﬀusion, with small particles being
more readily absorbed into blood than large particles [34]. Jani, et al., found a size-
dependent uptake of polystyrene particles for the range 50-3000 nm through the GI
mucosa [30].
It should be noted that these products do not enter general circulation directly.
Instead, the blood ﬁrst travels from capillaries of the gastrointestinal tract to the
liver via the hepatic portal vein, where it then enters capillaries in the liver for pos-
sible biotransformation or capture. Note that for nanoparticles, biotransformation
(metabolism) is not believed to occur.
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2.1.2.3 Liver.
The structure of the liver is comprised of liver cells, called hepatocytes, arranged in
thin layers in a radial pattern around a central vein. Hexagonal blocks of such layers
are called lobules. Spaces, called sinusoids, exist between the layers of hepatocytes
and are supplied by two sources of blood. First, the liver is supplied by arterial blood
from the hepatic artery. Second, the liver is supplied by the hepatic portal vein, which
transports blood from the gastrointestinal tract and spleen. This physiological feature
prevents contaminants from entering systemic circulation directly and is called the
“ﬁrst-pass eﬀect”. Combined, these two supplies carry approximately 25% of systemic
circulation to the liver at any given time [18]. See Figure 3.
Figure 3. Cross-Sectional View of Liver Lobule (from wikipedia.org)
It should be noted that the liver is more commonly known for its ability to metab-
olize small molecules, using various enzymes resident in the liver. Although nanopar-
ticles do not appear to undergo such metabolism, the liver is part of the reticuloen-
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dothelial system (RES) and has a large number of phagocytic cells to remove foreign
material. Phagocytic cells in the liver, called Kupﬀer cells, can trap foreign material
passing by engulfment.
In addition, the endothelial cells lining the sinusoids have small pores called
fenestrae, typically 100-150 nm in diameter, which allow passage of nanoparticles
to parenchymal cells (hepatocytes), where endocytic processes occur for uptake of
smaller particles [20]. Solutes (and foreign material) in the blood pass between en-
dothelial cells of the walls lining the sinusoids, beyond which are the hepatocytes.
After interaction with hepatocytes, blood exits through hepatic vein and out of the
liver. In addition, the liver also produces bile which is a clearance mechanism for
toxicants [16]. It is stored in the gallbladder prior to discharge to the duodenum
(upper small intestine), where it can then be excreted along with feces. Potential
damage to the liver includes lesions, such as inﬂammation or necrosis (i.e., localized
death of cells) [54].
2.1.2.4 Kidneys.
The kidneys are a major ﬁltering system to eliminate toxicants ﬂowing in blood
and excrete them via urine. Like the liver, they receive a considerable amount of
cardiac output (approximately 25%), or approximately 1.2-1.3 liters of blood per
minute. The nephron is the functional unit of the kidney, each of which contains
glomeruli, which are small tufts of blood capillaries. These capillaries have small
fenestrations which allow glomerular ﬁltration of blood with transit across Bowman’s
Capsule. See Figure 4 on the following page. Once across, the ﬂuid (e.g., water and
electrolytes) is either reabsorbed into blood or excreted. A particle diameter <5.5 nm
is the threshold for glomerular ﬁltration, hence the possible removal of nanoparticles
through excretion to urine [43].
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Figure 4. Kidney glomerulus, surrounded by Bowman’s Capsule (from wikipedia.org)
2.1.2.5 Spleen.
The spleen is the largest lymphatic organ in the body and has important immuno-
logical and ﬁltering functions [48]. It destroys old red blood cells while also serving
as a blood reservoir and is divided into segments, each having its own separate blood
supply. Each segment contains red and white pulp, with white pulp being lymphatic
tissue and the red pulp contains phagocytic cells [48]. It is an important part of
the reticuloendothelial system, with a large number of phagocytic cells available to
remove foreign material.
The spleen receives arterial blood from the splenic artery, which ﬂows into splenic
arterioles (surrounded by white pulp) and then capillaries. Instead of ﬂowing directly
into venules, these capillaries ﬁrst empty into the red pulp. From there, the blood
ﬂows into venous sinusoids. To leave the sinusoids, blood elements (including par-
ticles) must pass through openings in the sinusoids, called interendothelial slits (or
fenestrations). Therefore, it is believed that red pulp provides a ﬁltering function
for the spleen with clearance (i.e., capture) of larger particles (>250 nm dia.) [18].
Once through the interendothelial slits, blood enters venous ﬂow by passing through
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through the splenic vein and reaching the portal vein (i.e., portal circulation leading
to the liver).
Figure 5. Spleen anatomy (from wikipedia.org)
2.1.2.6 Brain.
The brain is of special interest to researchers, especially with nanoparticles being
shown to induce the production of reactive oxygen species and oxidative stress, both
of which have been linked to neurodegenerative diseases such as Parkinson’s and
Alzheimer’s [32, 6]. Besides possible harmful eﬀects, nanoparticles can be used for
beneﬁcial purposes, such as carriers of pharmaceuticals. Two goals of pharmaceutical
companies are to either avoid opsonization of nanoparticles by covering them with
hydrophilic polymer coatings (e.g., PEG) or by attaching speciﬁc ligands for brain
targeting [59, 29].
The phagocytic cells, such as those in the liver and spleen, help limit the exposure
of nanoparticles at the cerebrovasculature as they can remove a signiﬁcant percentage
of nanoparticles [45]. But once nanoparticles reach the brain, normally physiologic
processes are in place which eﬀectively protect the brain from foreign material, in-
cluding nanoparticles. The blood-brain barrier (BBB) serves to protect neurons from
systemic circulation agents/toxins by forming a very tight capillary barrier (i.e., very
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tight junctions between endothelial cells lining the blood capillaries of the brain). It
forms a physical barrier with a negative electrostatic charge between the blood vessels
and brain, which selectively restricts access of certain substances [8].
However, evidence suggests that nanoparticles may be able to overcome the BBB
due to their small size. Integrity of the BBB defense mechanism can also be com-
promised by speciﬁc circulatory diseases (e.g., hypertension) and brain inﬂammation
which increases the likelihood of toxicants, including nanoparticles, crossing over the
barrier.
In general, more specialized transport mechanisms are necessary to eﬀectively
overcome the tight junctions between endothelial cells lining the blood vessels of
the brain. Such mechanisms include active transport and carrier-mediated transport
[16, 27]. Kreuter’s research on using nanoparticles to deliver drugs through the BBB
describes the most likely transport mechanism as being endocytosis by the endothelial
cells lining the brain blood capillaries, with diﬀusion into the brain and subsequent
drug release within the cells [35].
Besides crossing the fairly tight barrier presented by the BBB, another route into
the brain exists through the olfactory nerve pathway following inhalation [23]. Re-
search indicates that the olfactory nerve pathway (nose-to-brain) should be considered
a route of entry to the central nervous system (CNS) of humans for inhalational expo-
sures to nanoparticles. Oberdo¨rster, et al. concluded that the CNS can be targeted
by ultraﬁne particles after deposition on the olfactory mucosa in the nasopharyn-
geal region, with subsequent translocation via the olfactory nerve to the olfactory
bulb within the brain [57]. Their research demonstrated that inhalation of carbon-13
(13C) ultraﬁne particles resulted in signiﬁcant increase in 13C in the olfactory bulb
over seven days [55]. This translocation pathway involving neuronal axons does not
apply to larger particles [57]. Remarkably, this pathway was ﬁrst described in 1941
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by Bodian and Howe, whose research on the 30 nm polio virus and exposures to pri-
mates revealed that the olfactory nerve and bulbs are routes of entry to the CNS for
intranasal instillation [58].
2.2 Cellular Transport
There are several known cellular transport processes that apply to biological sys-
tems, many of which have not been extensively modeled in PBPK models. Three such
examples include diﬀusion, active transport, and carrier mediated transport, which
have been cited in literature as possible transport processes for nanoparticles [41].
Although it is not known for certain which of these transport processes apply to
nanoparticles, there is value in beginning the modeling of such processes as it may
improve our understanding of the toxicokinetics of nanoparticles [84]. Therefore,
this work focuses on developing mathematical representations of these three cellular
transport processes for inclusion in a general nanoparticle PBPK model for compar-
ison against the traditional assumption of instantaneous equilibration. Doing so will
help guide future research and perhaps lead to the enhancement of nanoparticle risk
assessment by looking beyond traditional PBPK assumptions.
The exact mechanisms for transport of nanoparticles across cellular membranes
are debatable, but the two general categories of cellular transport are passive and
active transport. Notable processes under the passive transport family are diﬀusion
and carrier mediated transport. Although active transport also relies on “carriers”,
we recognize active transport as a separate process as it is a uni-directional process
with an ability to concentrate a solute against the concentration gradient. These three
transport processes (diﬀusion, active transport, and carrier mediated transport) are
the focus of this research.
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2.2.1 Simple Diﬀusion.
The ﬁrst cellular transport process included as a possible explanation for the
movement of nanoparticles is diﬀusion. Simple diﬀusion is based on Fick’s First Law
(of Diﬀusion) and is dependent on the concentration gradient, such as that between
two compartments. Net diﬀusion will cease when the concentration gradient=0. Flow
between the compartments is bi-directional.
For the mathematical representation, a transfer coeﬃcient, T, is used to char-
acterize the rate of transfer of nanoparticles between compartments. The transfer
coeﬃcient, T, represents the P×A product (permutation constant × surface area)
that would be found in in vitro research, but is unknown in this case.
Equation 1 shows a hypothesized mathematical representation for diﬀusion, with
a partition coeﬃcient 푃2:1 deﬁned in terms of concentrations 퐶1 and 퐶2. The parti-
tion coeﬃcient describes the distribution (ratio of the concentrations) of a chemical,
compound, etc., in two phases/media when at equilibrium. Simple diﬀusion includes
paracellular diﬀusion (permeating the cell membrane by traveling through aqueous
pores between cells) and transcellular diﬀusion (traveling through the cells them-
selves) [34].
Diﬀusion Transport Rate = 푇 ×
(
퐶1 − 퐶2
푃2:1
)
(#particles/hour) (1)
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where
푇 = transfer coeﬃcient (liters/hour)
퐶1 = concentration in subcompartment 1 (#particles/liter)
퐶2 = concentration in subcompartment 2 (#particles/liter)
푃2:1 = partition coeﬃcient from 2:1 (unitless)
2.2.2 Active Transport.
Active transport relies on speciﬁc protein molecules to serve as carriers, allowing
substances to move across the cell membrane. The protein molecules are selective in
which substances can be carried across the cellular membrane. Transport occurs inde-
pendent of the concentration gradient, thus allowing a substance to move from regions
of lower concentration to higher concentration [80]. The material that is transported
binds to the carrier molecule for transport into or out of the cell. As travel across the
membrane is against the concentration gradient, the cell must expend energy that is
usually derived from adenosine triphosphate (ATP). The energy is necessary as the
protein molecule changes shape in order to move the substance. An example of active
transport is the sodium-potassium pump, which facilitates movement of sodium and
potassium across cellular membranes.
As active transport relies on the availability of a protein molecule carrier to trans-
port a substance across the cellular membrane, it is assumed that loading up of carriers
is saturable. This saturable rate of transport is modeled here using Michaelis-Menten
kinetics, which is more commonly seen in metabolism processes for chemicals in the
liver. By convention, Michaelis-Menten kinetics are traditionally represented using
푉max and 퐾m. 푉max represents the maximum rate of transport (i.e., at full saturation
of the carrier), while the Michaelis-Menten constant, 퐾m, represents the concentration
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of nanoparticles prevailing when the transport rate is half of 푉max (i.e., 50% satura-
tion of the transporter protein). The general equation representing active transport,
assuming Michaelis-Menten kinetics, is shown in Equation 2.
Active Transport Rate =
푉max ⋅ 퐶
퐾m + 퐶
(#particles/hour) (2)
where
푉max = max rate of transport (#particles/hour)
퐶 = concentration (#particles/liter)
퐾m = Michaelis-Menten constant (#particles/liter)
At low and high concentrations, Equation 2 can be simpliﬁed as shown in Equa-
tion 3. More speciﬁcally, at low concentrations the rate of transport behaves linearly
with respect to concentration since 푉푚푎푥/퐾푚 is a constant. At higher concentrations,
this rate saturates and is approximated by the constant, 푉푚푎푥.
Active Transport Rate ≈
⎧⎨⎩
푉max ⋅ 퐶
퐾푚
, 퐶 ≪ 퐾푚
푉max, 퐾푚 ≪ 퐶
(3)
2.2.3 Carrier Mediated Transport.
Similar to active transport, carrier mediated transport also relies on protein car-
riers to transport a material across the cell membrane. These carriers can transport
ions and uncharged solutes, with some carriers transport single solutes while others
can transport 2-3 solutes at a time (single substrate and multiple substrate carriers).
Carrier-mediated transport is typically found when a molecule is too large to dif-
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fuse through pores of the cell membrane or low lipid solubility and an electrical charge
inhibits movement [33]. Carrier-mediated transport is also assumed to be saturable
process. Assuming carrier mediated transport can occur in either direction and that
there are two separate carriers involved, two sets of Michaelis-Menten constants are
used to represent the saturable rates. See Equation 4.
Carrier Mediated Transport Rate =
푉max1 ⋅ 퐶1
퐾m1 + 퐶1
− 푉max2 ⋅ 퐶2
퐾m2 + 퐶2
(#particles/hour) (4)
where
푉max1 = max rate of transport, from 1 to 2 #(particles/hour)
퐶1 = concentration in subcompartment 1 (#particles/liter)
퐾m1 = Michaelis-Menten constant, from 1 to 2 (#particles/liter)
푉max2 = max rate of transport, from 2 to 1 (#particles/hour)
퐶2 = concentration in subcompartment 2 (#particles/liter)
퐾m2 = Michaelis-Menten constant, from 2 to 1 (#particles/liter)
2.2.4 Phagocytosis.
Phagocytosis is a clearance mechanism in which large particles and microorgan-
isms are engulfed by the cell membrane, through formation of large vacuoles (aka vesi-
cles) which allow entry into the cell. Initially, foreign particles must bind to receptors
on the surface of the phagocyte, subsequently triggering a process in which pseu-
dopods extend outward and around the particles to form vacuoles. These vacuoles,
also known as phagosomes, are generally >250 nm in diameter [1]. Nicknamed “cel-
lular eating”, phagocytosis is the most prevalent clearance mechanism for deposited
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particles (ﬁne and course particles) in the alveolar region where it is performed by
alveolar macrophages [57]. Another example of phagocytosis is the capture of invad-
ing foreign cells (e.g., bacteria) by white blood cells.
Phagocytosis is mainly carried out by specialized cells, known as phagocytes. The
reticuloendothelial system (RES), which is also known as the mononuclear phagocytic
system (MPS), is a group of mononuclear cells originating from the bone marrow
which perform phagocytosis and remove small foreign particles from blood. Such
cells are found throughout the body, but the principal organs where macrophages are
found are the lungs, spleen, liver, and lymph nodes [18]. Lockman, et al., cites that
a large portion (80-85%) of nanoparticles are removed from vascular space by such
cells [45]. In mammals, this includes three classes of white blood cells: neutrophil
granulocytes (i.e., neutrophils), dendritic cells, and macrophages, of which the latter
are most common [1]. Neutrophils are the most abundant type of white blood cells
in humans. They are normally found in the blood stream, but can also concentrate
at sites of acute inﬂammation during chemotaxis.
However, the eﬃcacy of phagocytosis of nanoparticles is aﬀected by particle size.
For example, human alveolar macrophages are typically 14-21 휇m in diameter and
are most eﬀective at engulﬁng particles of comparable size. Particles that are much
larger or smaller may not be eﬀectively engulfed. Phagocytosis itself occurs within
6-12 hours after deposition, but actual clearance via the mucociliary escalator occurs
much slower, with retention half-times of solid particles in the alveolar region of
about 70 days in rats and up to 700 days in humans [57]. This longer retention time
is due to the dependence on random migration for phagocytized material to reach the
mucociliary escalator, which extends down to only the terminal bronchioli [37].
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2.3 Physiologically-Based Pharmacokinetic Modeling
Physiologically-based pharmacokinetic (PBPK) modeling, which has roots dating
back to 1924, has been a critical tool to both the pharmaceutical and toxicokinetic
communities. As in vivo research is very costly and time-consuming, physiologically-
based pharmacokinetic (PBPK) modeling is a valuable tool for exposure limit deter-
mination. It describes the time-course behavior of chemicals based on a mathematical
model that mirrors the physiological structure of the body[63].
PBPK models oﬀer the ability to estimate chemical concentrations in speciﬁc or-
gans or tissue by mechanistically considering whole tissue systems linked together
dynamically by blood ﬂow [68]. The body is treated as parallel compartments repre-
senting organs or tissues, with each compartment characterized by appropriate physio-
logical, physico-chemical, and biochemical parameters. Compartments can represent
single organs or can represent a family of tissues or organs. Tissues are consoli-
dated into a single compartment whenever feasible, unless the physiological, physico-
chemical or biochemical parameters have noticeably diﬀerent eﬀects on the chemical
uptake and disposition [39]. Examples of compartments used in PBPK models in-
cludes: adipose tissue, liver, brain, gastrointestinal tract, kidney, and lung.
Each tissue compartment is typically described with a mass balance ordinary
diﬀerential equation (ODE) in time which describes the change in the amount of
the chemical over time, typically in units of mass per time or number of particles
per time, in the case of nanoparticles. The general form of an ordinary diﬀerential
equation describing a compartment shows that the accumulation (or change in amount
per unit time) in any compartment is the sum of all input rates minus the sum of
all output rates. See Equation 5 on the following page. In addition, mass balance
must be maintained throughout the model, e.g., total blood ﬂow (cardiac output)
should equal the sum of blood ﬂows to the various compartments. The mass balance
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diﬀerential equations, which serve as a mathematical representation of the body, can
be numerically integrated to calculate the amount of contaminant in a tissue or organ
(i.e., compartment).
Accumulation = Rate of Transfer In - Rate of Transfer Out
⇒ d(Amount)
dt
=
∑
푄in퐶in -
∑
푄out퐶out (mass/time or # particles/time) (5)
In the absence of full data sets, PBPK models are useful as they can be used
for extrapolations within a species or even between species. Within a species, the
PBPK model can be combined with a limited set of experimental data to predict the
remainder of the concentration proﬁle for a chemical exposure. Scaling of parameters
can also be used to extrapolate between species and is best accomplished by using
published data (for tissue volumes, ﬂow rates, other physiological constants, etc.).
PBPK serves as an eﬀective tool to leverage both dose-response and mechanistic
data to more accurately predict human risk [12].
2.3.1 Parameterizing.
Model parameterization refers to establishing plausible physiological, physico-
chemical, and biochemical parameters necessary for use in the model equations [39].
Physiological properties include: body weight, organ weight, fractions of the body
allocated to each compartment, tissue blood ﬂow (i.e, blood ﬂow to and from tissue),
cardiac output, volume of tissues, and alveolar ventilation rate [15, 62]. Actual values
should be used whenever possible, but in the absence of such published data, param-
eter values can often be scaled using conversion factors (multipliers) from various
26
published research eﬀorts.
2.3.2 Traditional Assumptions of PBPK.
Many articles featuring PBPK modeling have appeared in literature [4, 9, 13,
14] and perhaps it was the Ramsey/Andersen model for styrene in 1984 which re-
popularized the use of PBPK models for toxicokinetics and pharmacology [61]. Such
models often include what might be referred to as the “traditional” assumption of
instantaneous equilibration between tissue and tissue blood of an organ. This tradi-
tional assumption is commonly used to describe pharmacokinetic behavior of volatile
organic chemicals in tissue. However, the assumption may not be suﬃcient to describe
nanoparticle time-course behavior as there are other physico-chemical properties of
nanoparticles (e.g., size, shape, surface area, surface charge) that likely cause a fun-
damental diﬀerence in behavior. In general, particles are known for being retained in
tissue, which is a property of potential toxicological signiﬁcance [62]. In other words,
nanoparticles are diﬀerent than molecules and this likely warrants a departure from
traditional PBPK modeling techniques.
Part of this assumption is the use of partition coeﬃcients, which represent the rela-
tive distribution of the chemical between two phases at equilibrium [39]. Throughout
many models, it is assumed that instantaneous venous equilibration exists which
allows the use of partition coeﬃcients to describe the relationship between concen-
trations in the compartment to the venous blood ﬂowing out of the compartment.
Whenever possible, partition coeﬃcients should be experimentally determined [65].
Figure 6 on the next page shows the calculation of concentration in venous blood C푣
using the partition coeﬃcient P.
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Instantaneous Equilibration
tissue
blood
where    P=partition coefficient
             Conc = concentration of analyte in a tissue
             Conc = concentration of analyte in venous blood
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Blood
• Instantaneous venous equilibration
– Use of partition coefficients
– Typical assumption for VOCs
tissue
blood
ConcP=
Conc
Figure 6. Tissue-to-blood partition coeﬃcient
2.4 Current State of Nano Risk Assessment
“It is neither feasible nor sensible to conduct safety evaluations for all
nanomaterials in current or future production; therefore, a risk assess-
ment paradigm should be ﬂexible and based on current knowledge of similar
materials.” - Igor Linkov, et al. [44]
2.4.1 Risk Assessment Frameworks.
Currently, there is no comprehensive risk assessment framework for nanomaterials,
primarily due to the lack of toxicologic data on engineered nanoparticles [57]. In
addition, there is a lack of adequate information describing the relationships between
external exposure, disposition, and internal (target organ) dose. More information
is necessary about characteristics of barriers to nanoparticles reaching target tissue
(e.g., respiratory tract, skin, gut, and blood-brain barrier) and the kinetics for uptake,
transport, and clearance of nanoparticles [44]. Beyond toxicological aspects, more
information is also necessary on the plausibility of exposures (i.e., real-world exposure
concentrations) [44].
The lack of such data prevents the National Institute for Occupational Safety
and Health (NIOSH), which is responsible for conducting research and making rec-
ommendations to the Occupational Safety and Health Administration (OSHA) and
other regulatory agencies, employers, workers, and the general public [52], from mak-
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ing recommendations for exposure limits for engineered nanomaterials. In addition,
OSHA itself does not have a permissible exposure limit (PEL) speciﬁc to engineered
nanomaterials.
The current risk assessment paradigm generally involves toxicologic testing as the
basis for addressing potential risk. Relying on this paradigm, it could take decades
before a thorough data set exists, due to the thousands of nanoparticle variants
possible as they are engineered to attain very speciﬁc properties.
In the absence of exposure limits, emphasis has been placed on determining oc-
cupational safety and health best practices to protect workers during production,
handling, and use of nanomaterials. NIOSH recommends that workplaces implement
risk management programs to emphasize such best practices. Risk management is
an integral part of an overall occupational safety and health program for workplaces
producing or using nanomaterials. A necessary part of any risk management program
is to implement the hierarchy of controls [51], which is: 1) elimination 2) substitution
3) engineering 4) administrative 5) personal protective equipment
Due to the diﬀerences presented by engineered nanoparticles, coupled with the
rapidly expanding nanotechnology ﬁeld as a whole, a strategic plan has been devel-
oped by NIOSH to address data gaps. This plan is designed to guide their research
on occupational safety and health concerns related to nanotechnology and includes
10 critical topic areas, with one of them being “risk assessment” [51].
In the NIOSH plan, the ﬁrst goal regarding risk assessment focuses on utilizing
existing exposure-response data for ultraﬁnes to identify potential hazards and as-
sess potential risks of occupational exposures to nanomaterials. Ultraﬁnes (<100
nm) include such particles as coal dust, welding fumes, combustion byproducts, etc.
Much can be learned from legacy data, but note that these are not engineered parti-
cles (i.e., not intentionally produced) and so they may exclude the physico-chemical
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properties driving the unique toxicological behavior. Another diﬀerence between ul-
traﬁnes and engineered nanoparticles is that ultraﬁnes are polydisperse (i.e., of many
sizes), whereas manufacturers of engineered nanoparticles purposely strive to pro-
duce monodisperse (i.e., of a single size) particles. A second goal is to develop a new
framework for assessing potential hazards, using new toxicologic data [51].
Since 2005, NIOSH activities for advancing risk assessment have included ana-
lyzing existing data on titanium dioxide (TiO2), developing lung deposition models,
performing extensive literature reviews on ultraﬁnes, developing hazard and risk es-
timates for carbon and metal nanoparticles using new NIOSH toxicity data, and
calibrating models using new toxicity data. Future risk assessment research planned
for ﬁscal years 2011-2012 includes evaluating/validating exposure-dose response mod-
els, investigating models with additional routes of exposure, developing risk estimates
using models, and characterizing risk of nanoparticle exposure in the workplace [52].
2.4.1.1 Framework Shortfalls.
Even with this extensive on-going research agenda, the current risk assessment
framework based on using existing knowledge on similar sized non-engineered particles
has many shortfalls. As stated earlier, using research data from ultraﬁnes generated
during combustion processes, welding, and mining dust does not factor in the unique
toxicological eﬀects due to engineered properties of nanoparticles, such as increased
surface area of nanoparticles leading to higher biological activity. In addition, the
framework does not even begin to address even a fraction of the sheer number of
nanoparticle variants that are possible.
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2.4.2 Existing Models.
Although there are many PBPK models in literature, most focus on chemicals and
not particle biokinetics. Models that are speciﬁc to nanoparticles are primarily fo-
cused on the lungs. Several very detailed lung models exist in the literature, including
those by Tran et al. and Kuempel [79, 78, 40]. These models address the complex-
ities presented by nanoparticles, including deposition, sequestration, phagocytosis,
and interstitial translocation in the lungs.
Figure 7 on the following page shows the hypothesized model of Tran and Don-
aldson, which is perhaps the ﬁrst one published speciﬁc to nanoparticles and serves
as a baseline for this dissertation research. In the next chapter, the methodology to
construct and analyze a PBPK model is described.
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Figure 7. Hypothesized PBPK model for nanoparticles (from Tran/Donaldson)[77]
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III. Methodology
“Essentially, all models are wrong, but some are useful. ”
- George Box
3.1 Phase I: Model Formulation
Developing an overall model of human exposures to nanoparticles is especially im-
portant in the absence of extensive in vivo research and published exposure standards
on a limitless variety of engineered nanomaterials that are possible. As mentioned in
Shelley, et al., it is important to be able to translate the ﬁndings from the ever-growing
in vitro nanotoxicity data into in vivo eﬀects, in order to enhance risk assessment.
In their article, the authors underscore the importance of developing PBPK models,
which will also help accelerate development of nanoparticle risk assessment [68].
3.1.1 A Simple Three-Compartment Model.
To describe how the PBPK model for this research was developed, ﬁrst consider
two compartments linked together by a third compartment as shown in Figure 8. The
lines with arrows represent systemic blood ﬂow, with Q denoting blood ﬂowrate (liter-
s/hour) and C denoting nanoparticle concentration (# particles/liter). The product
of Q⋅C represents a rate term (# particles/hour). Compartment 3, which is where
contributions from compartments 1 and 2 are combined, is representative of the lung
compartment.
As described earlier in Section 2.3 on page 25, we can denote the accumulation in
any compartment as:
Accumulation =
change in amount
time
=
푛∑
푖=1
Input푖 −
푚∑
푗=1
Output푗 (6)
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Compartment 1
Compartment 2
Compartment 3
QcCa
Q1Ca
Q2Ca
Q1Cv1
Q2Cv2
Q1Cv1 + Q2Cv2
Figure 8. Conceptual PBPK model, with three compartments
For the three compartments shown in Figure 8, the following ordinary diﬀerential
equations can be written as shown in Equations 7a to 7c on this page.
d(퐶1푉1)
d푡
= 푉1
d퐶1
d푡
= 푄1퐶푎 −푄1퐶v1 = 푄1퐶푎 − 푄1퐶1
푃1
(7a)
d(퐶2푉2)
d푡
= 푉2
d퐶2
d푡
= 푄2퐶푎 −푄2퐶v2 = 푄2퐶푎 − 푄2퐶2
푃2
(7b)
d(퐶푎푉3)
d푡
= 푉3
d퐶푎
d푡
= 푄1퐶v1 +푄2퐶v2 −푄푐퐶푎
=
푄1퐶1
푃1
+
푄2퐶2
푃2
−푄푐퐶푎 (7c)
where
퐶푥 = nanoparticle concentration (#particles per liter)
푉푥 = volume (liters)
푄푥 = blood ﬂowrate (liters per hour)
푃푥 = partition coeﬃcient (unitless)
We can then consolidate the system of ODEs into matrix notation, with the ﬁrst,
second, and third rows representing the ODEs for compartments 1, 2, and 3, re-
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spectively. Terms can be grouped, resulting in a matrix A multiplied by a vector of
concentrations, as shown below.
푉
d
d푡
⎡⎢⎢⎢⎢⎣
퐶1
퐶2
퐶푎
⎤⎥⎥⎥⎥⎦ = Input - Output (8a)
=
⎡⎢⎢⎢⎢⎣
푄1퐶푎
푄2퐶푎
푄1퐶1
푃1
+
푄2퐶2
푃2
⎤⎥⎥⎥⎥⎦−
⎡⎢⎢⎢⎢⎢⎣
푄1퐶1
푃1
푄2퐶2
푃2
푄푐퐶푎
⎤⎥⎥⎥⎥⎥⎦ (8b)
=
⎡⎢⎢⎢⎢⎣
0 0 푄1
0 0 푄2
푄1
푃1
푄2
푃2
0
⎤⎥⎥⎥⎥⎦
⎡⎢⎢⎢⎢⎣
퐶1
퐶2
퐶푎
⎤⎥⎥⎥⎥⎦−
⎡⎢⎢⎢⎢⎢⎣
푄1
푃1
0 0
0
푄2
푃2
0
0 0 푄푐
⎤⎥⎥⎥⎥⎥⎦
⎡⎢⎢⎢⎢⎣
퐶1
퐶2
퐶푎
⎤⎥⎥⎥⎥⎦ (8c)
=
⎡⎢⎢⎢⎢⎢⎣
−푄1
푃1
0 푄1
0 −푄2
푃2
푄2
푄1
푃1
푄2
푃2
−푄푐
⎤⎥⎥⎥⎥⎥⎦
⎡⎢⎢⎢⎢⎣
퐶1
퐶2
퐶푎
⎤⎥⎥⎥⎥⎦ (8d)
As V=diagonal matrix of the subcompartment volumes, we can write 푉 −1 as follows:
푉 =
⎡⎢⎢⎢⎢⎣
푉1 0 0
0 푉2 0
0 0 푉3
⎤⎥⎥⎥⎥⎦⇒ 푉 −1 =
⎡⎢⎢⎢⎢⎢⎣
1
푉1
0 0
0
1
푉2
0
0 0
1
푉3
⎤⎥⎥⎥⎥⎥⎦
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Therefore,
⇒ d
d푡
⎡⎢⎢⎢⎢⎣
퐶1
퐶2
퐶푎
⎤⎥⎥⎥⎥⎦ = 푉 −1
⎡⎢⎢⎢⎢⎢⎣
−푄1
푃1
0 푄1
0 −푄2
푃2
푄2
푄1
푃1
푄2
푃2
−푄푐
⎤⎥⎥⎥⎥⎥⎦
⎡⎢⎢⎢⎢⎣
퐶1
퐶2
퐶푎
⎤⎥⎥⎥⎥⎦ (9a)
=
⎡⎢⎢⎢⎢⎢⎣
1
푉1
0 0
0
1
푉2
0
0 0
1
푉3
⎤⎥⎥⎥⎥⎥⎦
⎡⎢⎢⎢⎢⎢⎣
−푄1
푃1
0 푄1
0 −푄2
푃2
푄2
푄1
푃1
푄2
푃2
−푄푐
⎤⎥⎥⎥⎥⎥⎦
⎡⎢⎢⎢⎢⎣
퐶1
퐶2
퐶푎
⎤⎥⎥⎥⎥⎦ (9b)
=
⎡⎢⎢⎢⎢⎢⎣
− 푄1
푃1푉1
0
푄1
푉1
0 − 푄2
푃2푉2
푄푐
푉2
푄1
푃1푉3
푄2
푃2푉3
−푄푐
푉3
⎤⎥⎥⎥⎥⎥⎦
⎡⎢⎢⎢⎢⎣
퐶1
퐶2
퐶푎
⎤⎥⎥⎥⎥⎦ (9c)
=
⎡⎢⎢⎢⎢⎣ 퐴
⎤⎥⎥⎥⎥⎦
⎡⎢⎢⎢⎢⎣
퐶1
퐶2
퐶푎
⎤⎥⎥⎥⎥⎦ “Matrix Form” (9d)
Writing the system of ODEs in matrix form allows eigenvalues and eigenvectors
to be calculated, which can be used to determine the solution to the system and for
eigenvalue analysis. Both of these items will be discussed later on.
3.1.2 Additions to the Three-Compartment Model.
To extend this model further, we can include mechanisms such as a source term,
exchange between two compartments, and a loss mechanism. See Figure 9. Here, the
source term, s, is shown as a constant input to Compartment 3. We also expand the
model to include a subcompartment representing the tissue portion of an organ, to
demonstrate an exchange between blood and tissue. In this example, a blood sub-
compartment is connected to a tissue subcompartment with diﬀusion as the transport
36
process.
Compartment 1
Compartment 2a
Blood
Source, s
Loss, k
Compartment 3
Compartment 2b
Tissue
Diffusion
QcCa
Q1Ca
Q2Ca
Q1Cv1
Q2Cv2
Q1Cv1 + Q2Cv2
Figure 9. Three compartment model with source, exchange, loss
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The equations below show the formulation of the system of ordinary diﬀerential equa-
tions.
푉
d
d푡
⎡⎢⎢⎢⎢⎢⎢⎢⎣
퐶1
퐶2푎
퐶2푏
퐶푎
⎤⎥⎥⎥⎥⎥⎥⎥⎦
= Input−Output + Exchange− Loss + Source (11a)
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d푡
⎡⎢⎢⎢⎢⎢⎢⎢⎣
퐶1
퐶2푎
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3.1.2.1 Software Implementation.
Software such as STELLA R⃝, makes construction of PBPK and other types of
models a relatively simple procedure using drag-and-drop icons that are connected
together. Figure 10 shows the various objects that can be used in STELLA R⃝, along
with a visual example of how a simple PBPK compartment (i.e., organ) is quickly
modeled using those same icons. Stocks are used to model accumulation in compart-
ments or subcompartments and each stock yields an ODE. Flows are used to represent
rates of transport (either blood- or other ﬂow rate). Converters are used to implement
various physiological or transport parameters. Connectors (i.e., red arrows) are used
to connect icons together.PBPK Using STELLA®
• Stocks
• Flows
• Converters
• Connectors
Figure 10. STELLA R⃝ icons used for modeling [70]
Alternatively, using MATLAB R⃝ allows greater ﬂexibility as complex simulations
(e.g., for-loops, etc.) can be run and eigenvalue analysis can be performed. Although
the complexity of this research warrants use of MATLAB R⃝, an identical version of the
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model will be maintained in STELLA R⃝ , as it provides an easy-to-visualize pictorial
representation and can be used to help validate MATLAB R⃝ results as modiﬁcations
to the model are made. Additional beneﬁts of using MATLAB R⃝ include its more
powerful suite of ODE solvers (numerical methods), ﬂexibility, and overall robustness
when it comes to simulations and analysis of systems.
3.1.3 The PBPK Model.
The next phase of research included developing a whole-body human PBPK
model. First, a comprehensive literature review was conducted to identify the or-
gans critical to distribution and uptake, and also organs that could be toxicological
endpoints. This information, combined with physiology and anatomy fundamentals,
was used to begin developing the PBPK model. The methodology of assembling
ODEs for a simple three-compartment model in Sections 3.1.1 and 3.1.2 was used to
assemble the full PBPK model. The format of the matrices used for the full PBPK
model can be viewed in Appendix D on page 158.
The PBPK model includes compartments for the lungs, liver, gastrointestinal
tract, kidneys, spleen, brain, slowly perfused tissue, and other richly perfused tissue.
The lungs are an essential part to the model, as they provide the inhalational ex-
posure pathway for nanoparticles. It is modeled using more complexity than most
traditional PBPK models as deposition and clearance processes are included. More
traditional models often assume rapid equilibration across the alveolar walls, no sig-
niﬁcant metabolism (loss mechanism) in lung tissue, and negligible storage capacity
(buildup) in the lungs [65].
The liver, GI tract, kidneys, spleen, and brain are included due to their possible
role in transport, removal, and accumulation of nanoparticles [20, 57, 54]. The slowly-
and richly perfused tissue compartments account for the remainder of the human body
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to maintain mass balance. Slowly perfused tissue includes muscle, skin, and fat. Liver,
kidneys, spleen, brain, slowly-perfused, and richly perfused are modeled using blood,
extracellular, and intracellular subcompartments, whereas the GI tract is modeled
with two subcompartments (lumen and blood), due to its anatomical structure. See
Figure 11.
Spleen Blood
Extracellular
Intracellular
Brain Blood
Extracellular
Intracellular
Kidney Blood
Extracellular
Intracellular
Liver Blood
Extracellular
Intracellular
GI Blood
Lumen
Alveolar Air
Alveolar Surface
Mucosa
Alveolar Blood
Inhalation
Feces
Phagocytosis
Phagocytosis
Phagocytosis
Bile
Urine
Mucociliary
Escalator
Richly Perfused-
Blood
Extracellular
Intracellular
Slowly Perfused-
Blood
Extracellular
Intracellular
Figure 11. Full PBPK model for nanoparticle exposures
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Three primary design considerations for the PBPK model are inclusion of particle
deposition, translocation, and loss mechanisms. Particle deposition involves where in
the respiratory tract nanoparticles are deposited. Translocation describes the move-
ment of particles out of the respiratory tract. Various loss mechanisms are included
as they explain how nanoparticles can, in theory, be removed from the body. Full
explanations of these three design considerations are shown below.
3.1.3.1 Particle Deposition.
Given a constant inhalational source, these nanoparticles may undergo deposition
in the head-airways, tracheobronchial, or alveolar regions of the lungs. Deposition
behavior is based on size, with large particles >100 nm being primarily deposited
in the head-airways region of the respiratory tract. At sizes <100 nm, deposition
in the head-airways increases as size decreases, leaving fewer particles available for
deposition lower in the respiratory tract. See Figure 12.
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Figure 12. Deposition in the respiratory tract, based on particle size (adapted from
Hinds) [26]
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3.1.3.2 Translocation.
If deposited in the tracheobronchial or head-airways regions, particles may be re-
moved to the GI tract via mucociliary clearance. For the tracheobronchial region,
we simplify the model by assuming uniform nanoparticle distribution over the in-
ner surface of a cylinder, with uniform mucus transport velocity also. The rate of
nanoparticles exiting the tube via mucociliary clearance is calculated by multiplying
the surface area concentration (i.e., # of nanoparticles per area) by mucus trans-
port velocity and trachea perimeter. Particles leaving the trachea via mucociliary
clearance then travel to the GI tract thru ingestion.
Particles deposited in the alveolar region (i.e., deep lung) can undergo translo-
cation to reach systemic blood ﬂow and distribution throughout the body. Arterial
blood with a ﬂow rate equal to cardiac output, 푄푐, is distributed to the ﬁve primary
organs in the model (i.e., GI tract, spleen, liver, kidneys, and brain), with the bal-
ance of the body’s tissue being clustered as richly perfused tissue and slowly perfused
tissue.
It is also assumed that reverse translocation can occur (i.e., nanoparticles can
travel from alveolar blood back to the alveolar surface) as the barrier is only two cells
thick. However, the model does not include the ability for nanoparticles to leave the
alveolar surface and enter alveolar air, as no evidence suggests that nanoparticles can
be re-entrained into alveolar air, unlike chemicals.
3.1.3.3 Loss Mechanisms.
The primary loss mechanisms out of the system are through exhalation, urine,
feces, and phagocytosis. These loss mechanisms are critical as they explain how
nanoparticles leave the body and allow the system to approach steady state, as will
be discussed in Chapter 4.
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Understanding the physiology is critical to building an adequate PBPK model.
Several of the key physiological design features include:
∙ Primary exposure pathway is inhalational exposure
∙ Secondary exposure pathway: ingestion of nanoparticles cleared from the
respiratory tract due to mucociliary clearance
∙ Exhalation and phagocytosis are additional means of clearance from the
respiratory tract
∙ A simpliﬁed approach to model the respiratory system was used. More
complex models exist [67, 79, 78], but are beyond the scope of this research.
∙ GI tract was included as it receives particles cleared from the respiratory
tract and as GI blood must ﬂow ﬁrst to the liver before reaching systemic
circulation (i.e., “ﬁrst-pass eﬀect”)
∙ The spleen serves as a size-dependent ﬁltering mechanism which traps parti-
cles of large enough size; what is not ﬁltered can serve as additional burden
on the liver, similar to GI blood. Phagocytosis occurs in the spleen, also.
∙ The liver is similar to the spleen as it is a ﬁltering mechanism and has
phagocytosis present. Like the kidneys, it has a very large inﬂow of blood.
Besides phagocytosis, the liver can also excrete waste to the GI tract, via
bile.
∙ The kidneys allow particles that are small enough to pass through the
glomerulus (i.e., glomerular ﬁltration) for excretion via urine. Larger parti-
cles cannot pass across this glomerular boundary (aka Bowman’s Capsule)
and are presumably returned to systemic ﬂow. Reabsorption and secretion
are not modeled here.
∙ Phagocytosis is modeled as a ﬁrst-order loss and is present in the lungs, liver,
and spleen.
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Typically, bloodﬂow rates to each organ are expressed as fractions of cardiac output,
푄푐, with the sum total of the fractions equaling one. Organ volumes are commonly
derived from body weight, BW. This convention of using 푄푐 and BW allows for
allometric scaling, which is the scaling of parameters based on diﬀerent size mammals.
The values for 푄푐 and BW used in the model are shown in Table 1. Blood ﬂow
fractions, based on 푄푐, are shown in Table 2 on the next page and organ volume
fractions, based on BW, are shown in Table 3.
Table 1. Physiological parameters for the PBPK model
Physiological
Parameter Variable Value Reference Notes
blood ﬂow rates to organs:
Cardiac Output 푄푐 290 liters/hr [61] fractions of 푄푐
tissue volumes expressed
Body Weight BW 70 kg [76] as a function of BW
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Table 2. Fractions of cardiac output
Fraction of
Physiological Cardiac
Parameter Variable Output Reference Notes
Fraction of cardiac Net of 27% when
output to liver 퐿푄푓푟푎푐 0.06 [76] including portal circ.
Fraction of cardiac Includes GI tract
output to portal circ. 푃표푟푡푎푙푄푓푟푎푐 0.21 [76] and spleen
Fraction of cardiac Back-calculated:
output to GI 퐺퐼푄푓푟푎푐 0.195 – =portal - spleen
Fraction of cardiac
output to spleen 푆푝푙푄푓푟푎푐 0.015 [76]
Fraction of cardiac
output to kidneys 퐾푄푓푟푎푐 0.223 [21]
Fraction of cardiac
output to brain 퐵푄푓푟푎푐 0.134 [21]
Fraction of cardiac Adapted from
output to RPT 푅푄푓푟푎푐 0.206 [21] Gearhart et al.
Fraction of cardiac Adapted from
output to SPT 푆푄푓푟푎푐 0.167 [21] by Gearhart et al.
Table 3. Organ volumes
Fraction Resulting
of Volume
Organ Variable BW (liters) Reference Notes
Liver 퐿푉 푓푟푎푐 0.04 2.8 [21]
Kidneys 퐾푉 푓푟푎푐 0.0043 0.3 [21]
Spleen 푆푝푙푉 푓푟푎푐 0.002 0.14 – Assumed.
Brain 퐵푉 푓푟푎푐 0.0214 1.5 [21]
Richly Adapted from Gearhart et al.
Perfused 푟푝푡푉 푓푟푎푐 0.0323 2.3 [21] by subtracting oﬀ spleen
Slowly Adapted from Gearhart et al.
Perfused 푠푝푡푉 푓푟푎푐 0.7214 64 [21] by adding adipose
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Traditional PBPK modeling often treats organ volume as being synonymous with
tissue volume (i.e., treats blood volume as negligible), so few data exist detailing
appropriate volumes for the blood portion in organs or tissue groups. In addition, no
data were available detailing the amount of extracellular (i.e., “outside the cell”) and
intracellular (i.e., “inside the cell”). Instead, estimates for these three volumes are
shown in Table 4.
Table 4. Subcompartment volumes
Physiological % of
Parameter Variable Organ Volume Notes
Estimated since
Blood Volume 푉blood 10 not known
Estimated since
Extracellular Space Volume 푉extra 50 not known
Estimated since
Intracellular Space Volume 푉intra 40 not known
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3.1.4 Range Finding.
In traditional PBPK modeling, in vitro and in vivo data would be used to establish
the key physiological and transport parameters for the PBPK model. An iterative
approach is then taken, where the model mathematics are ﬁne-tuned to represent in
vivo results (i.e., model matches reality). Doing so, it creates a model that can then
be used for extrapolation to higher doses and from species to species.
A goal of the research was to take the baseline model shown in Section 3.1.3 and
insert the mathematical representations of the transport processes to begin exploring
the eﬀects of these processes on the biokinetics of nanoparticles in the body. For this
research, however, there are no deﬁnitive data to represent the transport parame-
ters shown in Table 5 on the next page and, therefore, the concept of range ﬁnding
was proposed. The goal of the range ﬁnding is not to determine 100% correct values;
rather, it is to perform a comparative analysis and identify reasonable values to enable
this explorative PBPK model. A single value is chosen for each transport parameter
and is used across all organs, in order to enable the model. Note that the transport
parameters will be modiﬁed later, based on physico-chemical properties suggested by
literature, to provide organ-speciﬁc behavior. This will be discussed later in Section
3.2.
Other parameters exist which are important to the PBPK model, but are of sec-
ondary importance as compared to the parameters described in Table 5 on the follow-
ing page. A summary of the transport parameters that are not part of range ﬁnding
is shown in Table 6 on the next page. Note that the partition coeﬃcients establish
the ratio of concentrations as they approach steady state, while the Michaelis-Menten
constants help deﬁne the steepness of the Michaelis-Menten curves, which are plots
of transport rate vs. concentration.
48
Table 5. Transport parameters needing range ﬁnding
Physiological
Parameter Variable Notes
Transfer Coeﬃcient,
blood-to-tissue 푇b:t For diﬀusion between blood and tissue
Transfer Coeﬃcient,
extra-to-intracellular 푇e:i For diﬀusion between extra- and intracellular
Active Transport, Saturable rate for active
Max Rate of Transport 푉maxat transport from extra- and intracellular
Carrier Mediated Transport, Saturable rate for carrier mediated
Max Rate of Transport 푉maxcmt1 transport from extra- to intracellular
Carrier Mediated Transport, Saturable rate for carrier mediated
Max Rate of Transport 푉maxcmt2 transport from intra- to extracellular
Table 6. Transport parameter values selected
Physiological Value
Parameter Variable Chosen Notes
Partition Coeﬃcient
tissue-to-blood 푃t:b 2 Estimated since not known.
Partition Coeﬃcient
intra-to-extracellular 푃i:e 3 Estimated since not known.
Active Transport, Estimated since not known.
Michaelis-Menten Const. 퐾mat 1 Active transp extra- to intra-.
Carrier Mediated, Estimated since not known.
Michaelis-Menten Const1 퐾mcmt1 1 Carrier med. from extra- to intra-.
Carrier Mediated, Estimated since not known.
Michaelis-Menten Const2 퐾mcmt2 1 Carrier med. from intra- to extra-.
3.1.4.1 Range Finding for 푇b:t.
The ﬁrst transport parameter needing range ﬁnding (Table 5) is the blood-to-tissue
transfer coeﬃcient, 푇b:t, for diﬀusion between blood and tissue in the various organs.
For this portion of range ﬁnding, each organ is represented using two subcompart-
ments (i.e., blood and tissue). IE is a long-standing, traditional modeling technique
used in PBPK modeling and as it represents the fastest a compartment can “load up”,
it is treated as an upper bound. A single value for 푇b:t is selected by ﬁnding a value
that best keeps all organ concentrations in mid-range between the concentrations seen
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while using IE and zero. Mid-range was chosen as it provides concentration results
distinguishable from IE, while avoiding near-zero concentrations which will not pro-
vide meaningful insight into organ behavior. For some organs, concentration remains
fairly constant even as 푇b:t is varied, so determining a true mid-range value is not
possible.
3.1.4.2 Range Finding for 푇e:i.
To do range ﬁnding on 푇e:i, we ﬁrst insert the value for 푇b:t chosen during the
exercise described in the paragraph above, which deﬁnes the diﬀusion behavior be-
tween blood and extracellular. As 푇e:i represents the transport parameter govering
diﬀusion between extracellular and intracellular, the model is changed to the three-
subcompartment setup (i.e., blood, extra-, and intracellular). 푇e:i is then varied over
a range to ﬁnd a single value that can be used across all organs. In the absence of
quantitative data describing reasonable tissue concentrations for diﬀusion between
extracellular and intracellular environments, a 푇e:i value was chosen that keeps con-
centrations within 2× those seen by using the value of 푇b:t chosen in the previous
step. Although an arbitrary value, using this criteria results in concentrations within
reason (i.e., not inexplainably large).
3.1.4.3 Range Finding for 푉maxat.
Range ﬁnding for 푉maxat, which is the Michaelis-Menten maximum rate for active
transport from extracellular to intracellular, relies on a three-subcompartment rep-
resentation for each organ. For this simulation, active transport and diﬀusion work
in parallel between extra- and intracellular subcompartments. 푉maxat is varied over
a range of values and the goal is to choose a value for 푉maxat that best keeps con-
centrations within 2× those seen by using the value of 푇e:i chosen in the previous
50
step. Using this criteria results in concentrations within reason, avoiding possibly
unrealistic concentrations due to 푉maxat. The value chosen for 푉maxat is also used as
푉maxcmt1 since both represent saturable (Michaelis-Menten) terms in the extracellular-
to-intracellular direction.
3.1.4.4 Range Finding for 푉maxcmt2.
For this simulation, carrier mediated transport and diﬀusion are modeled as work-
ing in parallel between the extracellular and intracellular subcompartments. The goal
here is to choose a value for 푉maxcmt2 that best keeps concentrations within 2× those
seen by using the value of 푇e:i chosen earlier. Using this criterial avoids possibly
unrealistic concentrations in tissue due to 푉maxcmt2.
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3.1.5 Eigenvalue Analysis.
3.1.5.1 Eigenvalue Overview.
We use linear algebra to represent a system of diﬀerential equations by ﬁrst de-
riving a square matrix, A, representing the physiological and transport parameters
appearing in the concentration terms of the linear diﬀerential equations as described
in Sections 3.1.1 to 3.1.2 on pages 33–36. The system is of the form:
d
dt
⎡⎢⎢⎢⎢⎣
퐶1
퐶2
퐶푎
⎤⎥⎥⎥⎥⎦ = Input−Output + Exchange− Loss + Source (12a)
=
⎡⎢⎢⎢⎢⎣ 퐴
⎤⎥⎥⎥⎥⎦
⎡⎢⎢⎢⎢⎣
퐶1
퐶2
퐶푎
⎤⎥⎥⎥⎥⎦+ Source (12b)
This system can be rewritten in the form
˙⃗푐 = 퐴푐⃗+ 푠⃗ (12c)
where
˙⃗푐 = vector of time derivative concentrations,
dC
dt
퐴 = matrix of physiological and transport parameters
푐⃗ = vector of concentrations, with initial condition 푐⃗(0) = 0
푠⃗ = vector for the exposure source
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Once in matrix form, the solution to the system can be found by determining the
eigenvalues, 휆, and the associated eigenvectors, 푣⃗, of the A-matrix. The equation
A푣⃗=휆푣⃗ (푣⃗ ∕=0) characterizes the nature of the (휆, 푣⃗) pair. The eigenvalue satisﬁes the
property that the determinant of (A - 휆I)=0, where I=identity matrix. Explanations
of eigenvalues and eigenvectors are shown below:
Explanation. An eigenvalue is a time scale indicating the rate of growth or
decay for a given subcompartment.
Explanation. An eigenvector represents the distribution of the concentra-
tions across subcompartment for a given time scale (eigenvalue).
Explanation. The eigenstructure is the set of paired eigenvalues and eigen-
vectors.
For this research, the eigenstructure for an A-matrix is displayed using a matrix
with the eigenvalues in the top row and associated eigenvectors listed beneath the
eigenvalues. See Figure 13. Terms comprising each eigenvector are normalized us-
ing the L1-norm, such that the sum of the absolute value of the terms equals one,
i.e.,
∑푛
푖=1 ∣푥푖∣ = 1. By normalizing, the terms in an eigenvector represent fractional
contributions of each subcompartment to the given time scale (i.e., eigenvalue).
⎡⎢⎢⎣
휆1 휆2 휆3 ⋅ ⋅ ⋅ 휆24
푣⃗1 푣⃗2 푣⃗3 ⋅ ⋅ ⋅ 푣⃗24
⎤⎥⎥⎦
Figure 13. Eigenstructure format for full 24-subcompartment model
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3.1.5.2 Writing the Solution to the Linear System.
Eigenvalues and eigenvectors are important as they can be used to write the
solution to the non-homogenous linear system of the form x’=Ax+g(t). For this
research, the system is written as shown in Equation 12c on page 52, given the initial
condition 푐⃗(0)=0.
The solution to the non-homogeneous linear system in Equation 12c can be written
as shown in Equation 13. The number of terms to be summed, 푛, is deﬁned by the
number of subcompartments (i.e., state variables). As an example, if there are three
subcompartments in the model (i.e., 푛=3), then the vector of concentrations, 푐⃗(t), will
be the summation of three terms related to three pairs of eigenvalues and eigenvectors,
(휆푘, 푣⃗푘). See Appendix E on page 167 or Boyce and DiPrima [7] for more details on
development of the solution.
푐⃗(푡) =
푛∑
푘=1
푓푘
−휆푘
(
1− 푒휆푘푡) 푣⃗푘 (13)
where
푓푘 = the 푘
th term of the vector 푓⃗ which is the
inverse of the eigenvector matrix ⋅ source vector
휆푘 = the 푘
theigenvalue, 휆, with 휆 ∕= 0 and k=1, 2,..., n
푣⃗푘 = the 푘
theigenvector, k=1, 2,..., n
As t→ ∞, the exponential terms in Equation 13 go to zero and the steady state
solution is
푐⃗ss =
푛∑
푘=1
푓푘
−휆푘 푣⃗푘. (14)
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Alternatively, the steady state solution can be found by setting ˙⃗푐=0 in Equa-
tion 12c on page 52 and solving for 푐⃗ss (steady state), i.e.,
As 푡→∞ 푐⃗(푡) ≈ 푐푠푠 = −퐴−1푠⃗ (15)
3.1.5.3 Interpretation of the Eigenvalues.
Larger magnitude (negative) eigenvalues cause more rapid decay of the exponential
terms, leading to a rapid approach to steady state concentrations (i.e., rapid buildup of
nanoparticles). Conversely, small magnitude (negative) eigenvalues indicate a slower
buildup/approach to steady state concentration [86, 85].
3.1.5.4 An Example of Eigenvalue Analysis.
Eigenvalue analysis can be applied on the entire model, but the example presented
here focuses on a single organ. For this example, we ﬁrst exclude all other organs, thus
reducing the model to a system of three ordinary diﬀerential equations. The input
source is ignored and the kidney output is looped around to become the kidney input.
An assumption is that a fraction of nanoparticles, e.g., 20%, is excreted via urine.
Here, the transfer coeﬃcient governing the diﬀusion process between extracellular
and intracellular subcompartments for the kidney is being varied. See Figure 14 on
the following page.
Using the technique described in Section 3.1.1 on page 33, the ODEs for the
three-subcompartment system can be written in matrix form with an A-matrix of
physiological and transport parameters multiplied by a vector of concentrations, as
shown in Equation 16 on the following page.
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Kidney Blood
Extracellular
Urine
QkCaQkCv
Tb:t(Cb - Ce/Pt:b)
Qk= kidney blood flow rate, liters/hr
Ca = nanoparticle concentration in arterial blood, x1000 particles/liter
Cv = nanoparticle concentration in venous blood, x1000 particles/liter
Tb:t = blood-to-tissue diffusion transfer coefficient, liters/hr
Cb = nanoparticle concentration in kidney blood, x1000 particles/liter
Ce = nanoparticle concentration in extracellular, x1000 particles/liter
Pt:b = tissue-to-blood partition coefficient (unitless)
Te:i = extra-to-intracellular diffusion transfer coefficient, liters/hr
Ci = nanoparticle concentration in intracellular, x1000 particles/liter
Pt:b = tissue-to-blood partition coefficient (unitless)
Intracellular
Te:i(Ce - Ci/Pi:e)
Figure 14. Subassemblies for the kidneys
퐴 ⋅ 푐⃗ =
⎡⎢⎢⎢⎢⎣
−푇b:t − 0.2 ⋅푄푘
푉푏
푇b:t
푃t:b푉푏
0
푇b:t
푉푒
− 푇b:t푃t:b푉푒 −
푇e:i
푉푒
푇e:i
푃i:e푉푒
0 푇e:i푉푖
− 푇e:i푃i:e푉푖
⎤⎥⎥⎥⎥⎦
⎡⎢⎢⎢⎢⎣
퐶푏
퐶푒
퐶푖
⎤⎥⎥⎥⎥⎦ (16)
Varying the transport parameters, such as during range ﬁnding, will yield a dif-
ferent A-matrix and, hence, a diﬀerent eigenstructure. Therefore, we can recalculate
the eigenvalues for subcompartments of the model to to observe model behavior as
a speciﬁc transport parameter is varied. Note that discerning the cause of behavior
changes may be diﬃcult if multiple parameters are changed simultaneously and, there-
fore, only one parameter is varied at a time. For a three-subcompartment model, the
resulting eigenstructure has three eigenvalues with associated eigenvectors, as shown
in Figure 15.
To demonstrate eigenvalue analysis, we can then increase the extracellular-to-
intracellular diﬀusion transfer coeﬃcient, 푇e:i, and determine the resulting eigenstruc-
tures as shown in Figure 16 on the next page. As described earlier, the eigenvalues are
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⎡⎢⎢⎣
휆1 휆2 휆3
푣⃗1 푣⃗2 푣⃗3
⎤⎥⎥⎦ (17)
Figure 15. Eigenstructure format for kidney three-subcompartment model
in the ﬁrst row, with corresponding eigenvectors below the eigenvalues. The eigen-
vectors of the matrices can be used to determine which eigenvalue (i.e., time scale)
each subcompartment predominantly operates at. In Figures 16a to 16f on this page,
the ﬁrst eigenvector (under the eigenvalue in column 1) has the largest value in the
ﬁrst row, which corresponds to the blood subcompartment. The second column has
its largest value in the second row, which corresponds to extracellular. Finally, the
third column has its largest value in the third row, corresponding to intracellular.
⎡⎢⎣ -600.5 -12.56 -0.262−0.9461 −0.1177 0.002445
0.05389 −0.8264 0.01753
0 0.05588 0.98
⎤⎥⎦ (1)
1
(a) 푇e:i=0.1
⎡⎢⎣ -600.6 -15.5 -1.061−0.9459 −0.09958 0.009981
0.05412 −0.6958 0.07147
0 0.2046 0.9185
⎤⎥⎦ (1)
1
(b) 푇e:i=0.5
⎡⎢⎣ -600.6 -19.56 -1.682−0.9449 −0.08796 0.01592
0.05437 −0.6102 0.1139
−0.0007554 0.3018 0.8702
⎤⎥⎦ (1)
1
(c) 푇e:i=1
⎡⎢⎣ -600.8 –55.71 -2.952−0.9393 −0.07167 0.02828
0.05671 −0.4661 0.2019
−0.004012 0.4623 0.7698
⎤⎥⎦ (1)
1
(d) 푇e:i=5
⎡⎢⎣ -601.2 -102.2 -3.217−0.9312 −0.07368 0.03091
0.06008 −0.4379 0.2205
−0.008702 0.4884 0.7486
⎤⎥⎦ (1)
1
(e) 푇e:i=10
⎡⎢⎣ -612.4 -467.2 -3.453−0.7276 −0.2221 0.03325
0.1452 −0.3438 0.2371
−0.1272 0.4342 0.7296
⎤⎥⎦ (1)
1
(f) 푇e:i=50
Figure 16. Eigenvalues and associated eigenvectors as 푇e:i is varied
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Knowing which eigenvalue (i.e., time scale) that a subcompartment predominantly
operates at allows plotting of eigenvalues for analysis. Figure 17 shows a plot of the
eigenvalues belonging to each subcompartment as 푇e:i is varied. As the plot is log-log
based, it is important to note that sloped lines indicate large changes in eigenvalues.
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Figure 17. Example: log-log plot of the eigenvalues for the kidney as 푇e:i is varied
For the blood subcompartment (red line), the eigenvalue remains a relatively
constant, large magnitude (negative) value, even as the transfer coeﬃcient is varied.
Rapid buildup of nanoparticles in the blood subcompartment occurs and it achieves
steady state quickly, regardless of the value of 푇e:i.
The blue line, representing kidney extracellular, shows that the magnitude of
the eigenvalue increases exponentially as 푇e:i is increased, which indicates that it
reaches steady state much faster at higher values of 푇e:i. In contrast, the green line
representing kidney intracellular shows the eigenvalue levels oﬀ as 푇e:i increases, which
indicates the subcompartment reaches steady state at a slower rate and that this rate
does not diﬀer at higher levels of 푇e:i. Therefore, increasing 푇e:i has the greatest eﬀect
on the extracellular subcompartment and has negligible eﬀect on kidney blood and
kidney intracellular.
Appendix E on page 167 provides further explanation on how the general- and
steady state solutions can be derived using eigenvalues and eigenvectors. The ap-
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pendix also extends the example shown in this section and details how the solution
is comprised of contributions from separate exponential terms representing diﬀerent
time scales.
In summary, the eigenvalue analysis not only provides a pictorial representation
of overall subcompartment behavior as a transport parameter is varied, but also can
identify speciﬁc ranges where perturbations in rate parameters cause large increases
in the eigenvalues. By identifying these ranges, future research can be focused and
considerable resources saved by avoiding unnecessary in vitro and in vivo research.
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3.2 Phase II: Inclusion of Physico-Chemical Properties
Now with the model complete, Phase II focuses on the eﬀects of particle size,
shape, and surface properties on model behavior. Shape, size, and surface properties
can vary tremendously across nanoparticles and these properties are major deter-
minants of the clearance kinetics, biodistribution, and toxicological impact of the
particles [25, 72, 10]. Size inﬂuences many aspects of particle behavior, including
degradation, ﬂow properties, clearance, and uptake mechanisms [10]. Greater surface
area per mass results in nanoparticles that are more biologically active than larger-
sized particles of the same chemistry [57]. The focus of this research is not on the
toxicological impact and, therefore nanoparticle properties such as surface area are
not included.
In Phase I (see Section 3.1 on page 33), the baseline PBPK model was purposely
developed without special consideration for particle size, shape, or surface properties
as the goal was to simply create an operational, whole-body model. For Phase I, the
general simplifying assumptions for the model included:
(1) An inhalational exposure occurs and involves particles small enough to undergo
interstitial translocation
(2) A constant 50% of the exposure goes to alveolar air and 50% to mucosa
(3) Each organ behaves similarly (e.g., same transport parameters apply across all
organs)
(4) Assume 20% of nanoparticles are excreted via urine in the kidney
To explore the impact of the physico-chemical parameters, key behaviors tied to
particle size, shape, and surface characteristics were linked with the various transport
parameters identiﬁed earlier in Section 2.2 on page 19. Whenever possible, speciﬁcs
mentioned in the literature were used to generate piecewise linear functions to cre-
ate modifying factors (“modiﬁers”) aﬀecting nanoparticle transport. When speciﬁcs
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were not available, qualitative zero-to-one linear modiﬁers were created to capture
what interrelationships between particle size/shape/surface properties and transport
behavior are mentioned in the literature. These modiﬁers are applied in appropriate
points in the model to modify the transport parameters.
3.2.1 Size-Related Eﬀects.
3.2.1.1 Size Eﬀects on Lung Processes.
The biokinetics of nanoparticles is diﬀerent than for larger particles as they are
eﬃciently deposited in all three regions of the respiratory tract: the head airways,
tracheobronchial, and alveolar regions. The head airways region includes the nose,
mouth, pharynx, and larynx. The tracheobronchial region, also known as the lung
airways region, includes the airways from the trachea to the terminal bronchioles.
The alveolar region (deep lung) is where gas exchange occurs [26]. Figure 18 shows
the three regions.
Head 
Airways
Tracheo-
bronchial
Alveolar
Figure 18. Regions of the respiratory tract (adapted from Oberdo¨rster, et al.) [57]
Figure 19 on the following page shows the deposition fraction of particles in the
three regions of the respiratory tract, based on particle diameter. Total deposition is
simply the sum of the head-airways, tracheobronchial, and alveolar deposition frac-
tion. The right-hand side of the ﬁgure shows that large particles, with aerodynamic
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diameters >1 휇m (or 1000 nm), are prone to deposition in the head airways [26].
This is due to inertial impaction, gravitational settling, and interception [57] and the
relative eﬀectiveness of the nasal hairs and bends in the airﬂow path through nasal
passages [26].
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Figure 19. Deposition in the respiratory tract, based on particle size (adapted from
Hinds) [26]
In contrast, diﬀusion dominates at smaller sizes and is the primary mechanism for
deposition of inhaled nano-sized particles in the respiratory tract. Deposition at the
smallest sizes (far left end of Figure 19) is predominantly in the head airways region,
due to the eﬀectiveness of the nasal structure. A dip in the deposition curves exists
over the size range of 100 nm to 1 휇m represents a minimum in deposition probability
[47], and is related to the transition from gravitational- to diﬀusion-dominated depo-
sition. Coincidentally, the 100 nm size is notable also as engineered nanoparticles are
commonly speciﬁed as being <100 nm in diameter.
The left-hand side of Figure 19 shows that for smaller particles (<0.01 휇m or 10
nm), deposition in the head airways, especially the nasal region, is dominant (due to
diﬀusion). This results in lower deposition rates in the tracheobronchial region (lung
airways) and alveolar region for these sizes [26].
Diﬀerences between total deposition during nasal and oral breathing are minimal
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for smaller particles [66]. For this research, an assumption of nose breathing is as-
sumed, as it is the exposure scenario used to derive the deposition curves shown in
Figure 19. Equations 18, 19, and 20 represent the curves and are estimates of the
deposition fraction, DF, in the three respiratory system regions [26]. These equations
can be used to more accurately specify the distribution of nano-sized particles to
the three regions of the respiratory tract during Phase II, instead of relying on the
assumptions in the baseline model listed in Section 3.2 on page 60.
DFHA =
[
1− 0.5
(
1− 1
1 + 0.00076푑2.8푝
)]
×
[
1
1 + exp (6.84 + 1.183 ln 푑푝)
+
1
1 + exp (0.924− 1.1885 ln 푑푝)
]
(18)
DFTB =
(
0.00352
푑푝
)
[exp(−0.234(ln 푑푝 + 3.4)2) + 63.9exp(−0.819(ln 푑푝 − 1.61)2)]
(19)
DFALV =
(
0.0155
푑푝
)
[exp(−0.416(ln 푑푝 + 2.84)2) + 19.11exp(−0.482(ln 푑푝 − 1.362)2)]
(20)
where
DFHA = deposition fraction in head airways region
DFTB = deposition fraction in tracheobronchial region
DFALV = deposition fraction in alveolar region
푑푝 = particle diameter, 휇m
Particle Clearance
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Particles deposited in the head- and tracheobronchial regions are cleared primarily
by the mucociliary escalator, in which the concerted action of cilia (hair-like struc-
tures) on the airway epithelial surface propels particles towards the larynx [38]. In
addition, a large number of particles deposited in the alveolar region are phagocytized
by macrophages [11], although literature suggests that eﬀectiveness may be dependent
on particle size. Phagocytosis will be discussed further in the following pages.
Interstitial Translocation
As mucociliary clearance and phagocytosis are not perfect defense mechanisms,
particles not rapidly removed can translocate from the alveolar region into the inter-
stitium (i.e., the tissue/space around the alveolar sacs) [57]. This is called interstitial
translocation. Numerous studies have conﬁrmed the existence of this translocation
pathway across the alveolar epithelium and into the bloodstream. Research indicates
that smaller particles (15 nm vs. 80 nm) had much higher interstitial translocation
[63, 36]. A summary of various studies showed that uncoated particles up to at least
100 nm appear to undergo interstitial translocation [57].
For this research, a modiﬁer called the interstitial translocation factor (ITF) was
deﬁned to specify a size range for which interstitial translocation occurs. A maximum
size of 100 nm was used with a sloped line introduced between 100-150 nm to avoid
discontinuity. See Figure 20 on the next page. ITF is multiplied by the translocation
rate for diﬀusion between alveolar surface and alveolar blood.
3.2.1.2 Eﬀects on Diﬀusion Between Blood and Tissue.
Nanoparticles traveling in systemic circulation must ﬁrst exit through the endothe-
lial walls of blood vessels to gain access to tissue, which is comprised of extracellular-
and intracellular spaces (i.e., outside of- and within the cell, respectively). The en-
dothelium is a thin layer of cells lining the interior of all blood vessels throughout the
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Figure 20. Interstitial translocation factor (ITF) (inferred from [63, 36, 57])
body and forms a relatively smooth surface to facilitate blood ﬂow. The endothelium
is a type of epithelial tissue, which is one of four types of biological tissue found in
animals (i.e., epithelial, connective, neural, and muscle tissue).
Most endothelium in the body is considered continuous, due to tight junctions
between the endothelial cells and an underlying basement membrane. These tight
junctions are gaps typically <2 nm wide, which serve as a physical barrier to impede
passage of particles between endothelial cells (i.e., paracellular transport). However,
the continuity of endothelial tissue varies from organ to organ, as demonstrated by
the very tight junctions in the brain (i.e., blood-brain barrier) while the liver, which
is fenestrated with pores of up to 100 nm, provides easier passage of material [8].
Figure 21 on the following page shows the hypothesized modiﬁer called the “para-
cellular transport eﬃciency factor” (PTEF), which governs paracellular transport for
diﬀusion between blood and tissue as shown in Equation 21 on page 67. It applies to
all the organs in the model, except for liver and spleen which are fenestrated and will
be discussed later.
PTEF is deﬁned with ‘1’ representing maximum transport eﬃciency (i.e., nanopar-
ticles are small enough to slip through the gaps) and ‘0’ representing large particles
that cannot slip through gaps. A value of 2 nm was chosen as the threshold for the
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PTEF modiﬁer, based on the typical gap width discussed earlier. The PTEF modiﬁer
is assumed to be continuous, in order to acknowledge that the threshold size is not
a precise value and that paracellular transport is not binary (i.e., completely on or
completely oﬀ).
0 1 2 3 4 5 6 7 8 9 10
0
0.2
0.4
0.6
0.8
1
Particle size (nm)
Pa
ra
ce
llu
la
r T
ra
ns
po
rt 
Ef
fic
ie
nc
y 
Fa
ct
or
Figure 21. Paracellular transport eﬃciency factor (PTEF) (inferred from [8])
Besides the paracellular route, particles can also pass through the cells via the
transcellular route [18]. Transcytosis, which combines the processes of materials en-
tering, transiting, and then exiting a cell, is believed to be size-dependent with smaller
particles passing through the cell more easily than larger particles [20]. Few data exist
describing the eﬀect of particle size on overall transcytosis rates, but research suggests
that nano-sized partricles more readily enter cells and cellular organelles than larger
particles [47].
Although there is a lack of quantitative information on the overall transcytosis
process (i.e, entering + transiting + exiting a cell), the ‘entering’ portion of the process
is fairly well-documented [22, 27, 35] and is known as endocytosis. Many articles
conclude that particles <100 nm are necessary for endocytosis to occur eﬃciently, but
more recent evidence by Garnett and Kallinteri concluded that sizes “in the hundreds”
of nanometers range undergo eﬃcient uptake into cells [20]. As the authors did not
specify a discrete value for an upper threshold, a value of 500 nm was chosen to deﬁne
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a modiﬁer called a “transcytosis eﬃciency factor” (TEF). See Figure 22. Note that
a sloped line was introduced between 500-600 nm to avoid discontinuity.
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Figure 22. Transcytosis eﬃciency factor (TEF) (inferred from [20])
For the purposes of blood-to-extracellular (i.e., blood-to-tissue) transport, we con-
sider diﬀusion to be the combined eﬀect of both the paracellular and transcytosis
processes. The original diﬀusion equation presented in Section 2.2.1 on page 20 is
rewritten to include both the paracellular and transcytosis modiﬁers, which modify
the transfer coeﬃcient, 푇b:t. See Equation 21. At sizes <10 nm, both processes are
in eﬀect, thereby increasing diﬀusion. At sizes 10-600 nm, only transcytosis applies
and above that size range diﬀusion of nanoparticles does not occur.
Modiﬁed Blood:Tissue Diﬀusion Rate = (PTEF + TEF) ⋅ 푇b:t ⋅
(
퐶blood − 퐶extra
푃t:b
)
(21)
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where
PTEF = paracellular transport eﬃciency factor (unitless)
TEF = transcytosis eﬃciency factor (unitless)
푇b:t = transfer coeﬃcient, blood-to-tissue (liters/hour)
퐶blood = concentration in blood (#particles/liter)
퐶extra = concentration in extracellular (#particles/liter)
푃t:b = partition coeﬃcent from tissue-to-blood (unitless)
Liver-Speciﬁc Phenomena
For diﬀusion between blood and tissue in any organ, it is assumed that paracellular
transport (i.e., between cells) and transcellular transport (i.e., through cells) occur.
But as discussed earlier, the continuity of blood vessel endothelium varies organ to
organ. Both the liver and spleen have fenestrations (pores) which in theory, allow
particles to cross out of blood and into tissue. See Figure 23. Research shows that
the liver allows materials up to 100 nm to pass through the endothelial wall into
extracellular space [20].
Figure 23. Diagram of fenestrations in blood vessels, (adapted from Garnett) [19]
Another unique feature involves the concept of “cell trapping”, in which particles
that are large enough are sequestered in tissue. This mechanical ﬁltration is not
clearly explained in the literature but appears to be a function of organ construction
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and microcirculation, with particles becoming trapped inside the tissue as blood must
pass through the sinusoid walls to exit into venous bloodﬂow. Being “trapped” inside
tissue appears to imply that foreign material is sequestered (i.e., prevented from
transport away from the organ in venous blood) and subsequently faces phagocytosis.
Because of organ construction, the spleen tends to be involved in clearance of larger
particles (>250 nm diameter), while the liver clears smaller particles [18].
These two features are discussed in the literature as reasons why the liver (and
spleen) are eﬀective in removing nanoparticles from circulation, with most articles
mentioning only one of the two possible explanations. This raises question on whether
removal of particles from circulation by the liver (and the spleen) is governed by a
maximum or minimum size limit [71]. Unlike most researchers, Stolnik et al., ac-
knowledge both the ﬁltration/cell trapping and fenestration theories and describes
how there appears to be a narrow size range for prolonged circulation of a pharmeu-
tical drug carrier [71]. To model this eﬀect, the maximum and minimum sizes must
be speciﬁed. For the maximum size for escape through fenestrations, a value of 100
nm was chosen, based on Garnett and Kallinteri [20].
As no minimum size could be found in the literature, a value of 200 nm was
chosen as it provides for the narrow size range phenomena described by Stolnik, et al.
[71]. This value appropriately reﬂects that the liver is involved with clearing smaller
particles than the spleen, which Garnett concluded will trap particles >250 nm [18].
Combining the two thresholds (i.e., 100 nm and 200 nm), a new modiﬁer called the
liver accumulation factor (LAF) was formed. See Figure 24 on the following page.
Note that in the narrow size range of 100-200 nm, the LAF plot suggests that
nanoparticles have decreased accumulation. Conversely, at sizes below and above
that range, particles will have increased accumulation in tissue (i.e., removal from
systemic circulation). To avoid having points of discontinuity between y-values of 0
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Figure 24. Liver accumulation factor (LAF) (inferred from [71, 20])
and 1 (i.e., step-down and step-up functions), more gradual transitions (sloped lines)
were inserted.
For the liver, LAF replaces the default paracellular modiﬁer, PTEF, and is added
to the transcytosis modiﬁer, TEF, as shown in Equation 22. The result is that
the fenestrations allow particles larger than the 2 nm threshold discussed earlier to
leave blood and enter tissue. At sizes greater than >200 nm, trapping occurs which
causes particle accumulation and decreased ability to return to blood (venous ﬂow).
Transcytosis occurs over a large range of particle sizes, up to the threshold of 500 nm.
Modiﬁed Liver Diﬀusion Rate = (LAF + TEF) ⋅ 푇b:t ⋅
(
퐶blood − 퐶extra
푃t:b
)
(22)
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where
LAF = liver accumulation factor (unitless)
TEF = transcytosis eﬃciency factor (unitless)
푇b:t = transfer coeﬃcient, blood-to-tissue (liters/hour)
퐶blood = concentration in blood (#particles/liter)
퐶extra = concentration in extracellular (#particles/liter)
푃t:b = partition coeﬃcent from tissue-to-blood (unitless)
Spleen-Speciﬁc Phenomena
Similar to the liver, it is assumed that accumulation of nanoparticles in the spleen
occurs above and below minimum and maximum size thresholds as the spleen also is
fenestrated and has cell trapping. But compared to the liver, the spleen tends to clear
larger particles from circulation as its discontinuous vascular endothelium has larger
fenestrations, which allow even larger particles to pass through [20]. For a maximum
size, Champion et al., deﬁnes a size threshold of 100 nm diameter, below which
particles are able to exit blood vessels through fenestrations in the endothelial walls
[10]. Conversely, Garnett concludes that particles >250 nm are eﬀectively trapped
[18] and this value serves as the minimum size threshold.
To accommodate the cell trapping and fenestration theories simultaneously, a
spleen accumulation factor (SPAF) was deﬁned using the two thresholds described
above. See Figure 25 on the following page. This factor is applied between spleen
blood and extracellular and replaces the paracellular modiﬁer, PTEF. It is added to
the transcytosis modiﬁer, TEF. See Equation 31 on page 108. At sizes greater than
>250 nm, particles tend to accumulate in extracelllular and are, in theory, less likely
to return to blood (venous ﬂow).
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Figure 25. Spleen accumulation factor (SPAF) (inferred from [10, 18])
Modiﬁed Spleen Diﬀusion Rate = (SPAF + TEF) ⋅ 푇b:t ⋅
(
퐶blood − 퐶extra
푃t:b
)
(23)
where
SPAF = spleen accumulation factor (unitless)
TEF = transcytosis eﬃciency factor (unitless)
푇b:t = transfer coeﬃcient, blood-to-tissue (liters/hour)
퐶blood = concentration in blood (#particles/liter)
퐶extra = concentration in extracellular (#particles/liter)
푃t:b = partition coeﬃcent from tissue-to-blood (unitless)
Kidney-Speciﬁc Phenomena
As described in Section 3.2 on page 60, a simplifying assumption used for the
model derived in Phase I of the research was that 20% of nanoparticles in the blood
entering the kidneys undergo glomerular ﬁltration and renal clearance by excretion
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via urine. This was based on the fact that approximately 20% of arterial blood ﬂowing
to the kidney undergoes glomerular ﬁltration, with the remaining 80% returning to
circulation [16].
However, glomerular ﬁltration is highly selective with respect to particle size and
has a size threshold of approximately 5-6 nm diameter [63]. For this phase of research,
a modiﬁer called the kidney ﬁltration eﬃciency factor (KFEF) was deﬁned, with a
value of 6 nm used as the maximum size for nanoparticles to undergo glomerular
ﬁltration. A gradual transition (sloped line) was inserted between 6-8 nm to avoid
having a discontinuity in the piecewise linear modiﬁer. At or above 8 nm, it is assumed
that no nanoparticles are removed via glomerular ﬁltration, thereby eliminating renal
clearance via urine. See Figure 26.
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Figure 26. Kidney ﬁltration eﬃciency factor (KFEF) (inferred from [63])
Brain-Speciﬁc Phenomena
The blood-brain barrier controls the passage of various substances from systemic
circulation into the central nervous system, CNS. Considerable literature exists that
states in various terms that the brain has “very tight junctions” in its endothelium,
eﬀectively eliminating the paracellular route for the brain. However, few authors
attempt to quantify the size of these tight junctions. Since it was stated previously
that the gaps between endothelial cells in the other organs are approximately 2 nm
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[8], then the premise that BBB junctions are more “tight” warrants assigning a small
gap size, such as 1 nm. See Figure 27.
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Figure 27. Brain paracellular eﬃciency factor (BPEF) (inferred from [8])
For the brain transcellular route, it is assumed that the same biokinetics apply as
described for the transcytosis eﬃciency factor (TEF). Substituting BPEF for PTEF,
the diﬀusion rate for the brain (blood-to-tissue) can be rewritten as shown in Equa-
tion 24.
Modiﬁed Brain Diﬀusion Rate = (BPEF + TEF) ⋅ 푇 ⋅
(
퐶blood − 퐶extra
푃t:b
)
(24)
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where
BPEF = brain paracellular eﬃciency factor (unitless)
TEF = transcytosis eﬃciency factor (unitless)
푇 = transfer coeﬃcient (liters/hour)
퐶blood = concentration in blood (#particles/liter)
퐶extra = concentration in extracellular (#particles/liter)
푃t:b = partition coeﬃcient from tissue-to-blood (unitless)
Inﬂammation, either naturally occurring or due to properties of the nanoparticles,
can cause “leaky” endothelium which allows materials into the tissue [18]. In addition,
the manipulation of nanoparticle pharmaceuticals for speciﬁc targeting of the brain
would likely present interesting results for the model. Both of these phenomena,
although interesting, are beyond the scope of this research.
3.2.1.3 Eﬀects on Phagocytosis.
The reticuloendothelial system, which includes the liver, spleen, and lymph nodes
[63], contains high concentrations of phagocytic cells which can remove foreign ma-
terial, including nanoparticles. As phagocytosis is part of the endocytosis family of
cellular transport processes and due to the lack of additional data, the modiﬁer used
to describe transcytosis (which involves endocytosis) in Section 3.2.1.2 on page 64 was
used. See Figure 28 on the next page. The modiﬁer, relabeled as the phagocytosis
size factor (PSF), is applied to the three sites for macrophages in the PBPK model
(i.e., lungs, liver, and spleen).
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Figure 28. Phagocytosis size factor (PSF) (inferred from [8])
3.2.1.4 Eﬀects on Diﬀusion Between Extracellular and Intracellu-
lar.
Exiting the blood circulatory system implies that nanoparticles have entered the
extracellular environment, where spaces between cells are ﬁlled with an aqueous gel-
like material [20]. Once in the extracellular environment, particles may undergo
uptake into cells through endocytic processes. As described earlier, recent evidence
by Garnett and Kallinteri concluded that sizes “in the hundreds” of nanometers range
undergo eﬃcient uptake into cells [20]. As no upper threshold was speciﬁed, a value
of 500 nm was chosen to deﬁne the threshold for a modiﬁer called a “cellular uptake
eﬃciency factor” (CUEF). See Figure 29 on the following page. CUEF is applied to
푇e:i, 푉maxat, 푉maxcmt1, and 푉maxcmt2 to modify the transport rates for diﬀusion, active
transport, and carrier mediated transport.
3.2.2 Shape-Related Eﬀects.
Although it seems likely that particle shape will aﬀect deposition, toxicity, and
fate of nanoparticles in the body, minimal research has been performed to describe
such behavior [31]. However, it is believed that departing from spherical shapes
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Figure 29. Cellular uptake eﬃciency factor (CUEF) (inferred from [20])
usually leads to decreased internalization of the particles into the cell, hence increased
biopersistence. A new modiﬁer called the cellular uptake shape factor (CUSF) was
deﬁned, where a value of ‘1’ indicates the ideal shape, presumed to be spherical. See
Figure 30.
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Figure 30. Cellular uptake shape factor (CUSF)
Although qualitative, the purpose of this modiﬁer, which ranges from 0 to 1, is to
explore how various shapes can aﬀect model behavior due to inhibition of nanoparticle
cellular uptake. CUSF is applied against 푇b:t, 푇e:i, 푉maxat, 푉maxcmt1, and 푉maxcmt2, as
it is assumed that shape can aﬀect diﬀusion (e.g., how easily particles move through
gaps), active transport, and carrier mediated transport. The various mathematical
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equations representing these processes are therefore multiplied by the CUSF modiﬁer
to reﬂect diminished rates of transport when particle shape departs from the ideal
case, which is assumed to be spherical.
Note that internalization is also dependent on particle orientation and mechanical
stiﬀness. For example, red blood cells are ﬂat and fairly large at 10 휇m, but can ﬁt
between cells if oriented correctly and due to their relative ﬂexibility. Similar to the
discussion earlier on including knowledge from pharmaceutical interaction with the
brain, these particle orientation/mechanical stiﬀness phenomena will likely provide
interesting results, but are beyond the scope of this research.
3.2.3 Surface Coating Eﬀects.
3.2.3.1 Eﬀects on Phagocytosis.
Phagocytosis is governed by both particle size and surface treatments. In general,
particles tend to have relatively hydrophobic surfaces and various blood proteins will
bind strongly to those surfaces [18]. Uncoated hydrophobic particles are typically
cleared from the bloodstream by the reticuloendothelial (i.e., phagocytic) system,
while more hydrophilic particles remain in circulation longer [72, 49, 73].
Phagocytosis by the major organs of the reticuloendothelial system (RES) is reg-
ulated by the presence and balance between two groups of blood components (i.e.,
plasma proteins). The ﬁrst component, opsonins, promote phagocytosis. The second
component, dysopsonins, work to suppress the process. Opsonins are proteinaceous
components of blood that adsorb onto particle surfaces or cells, eﬀectively making
foreign material more attractive to phagocytes [71]. Opsonins do not appear to be
essential for phagocytosis to occur, but the process is signiﬁcantly slower in their
absence [18]. By the addition of speciﬁc hydrophilic coatings, the opsonin plasma
proteins can be repelled which leaves the nanoparticles “invisible” to phagocytes [50].
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The addition of surface coatings using polyethylene glycol (i.e., “pegylation”), or
other hydrophilic surface coatings, to nanoparticles tends to increase the half-lives of
nanoparticles in circulation [18]. Macrophages, such as those in the liver and spleen,
are eﬀective in removing opsonized particles, but coating particles with hydrophilic
polymers such as polyethylene glycol (PEG) can reduce opsonization [20, 49]. This
leads to reduced rates of phagocytosis and prolonged circulation in blood. Phar-
maceutical research has long focused on developing hydrophilic, non-ionic polymers
(i.e., coatings) for nano-sized drugs to suppress opsonins by preventing their adsorp-
tion onto particle surfaces [72], thus avoiding drug elimination by phagocytes and
increasing the drug stability. For the pharmaceutical industry, premature removal of
nano-sized drugs or carriers transporting drugs by macrophages is highly undesirable.
Changing the amount or characteristics of the surface coating layer can aﬀect the
biodistribution [18], e.g., a less dense PEG layer may provide less eﬀective protection
against phagocytosis. A modiﬁer called the phagocytosis coating factor (PCF) repre-
senting the eﬀects of coatings on phagocytosis was created. A value of ‘1’ indicates a
lipophilic (i.e., hydrophobic) coating specially designed to allow nanoparticles to evade
phagocytosis (e.g., PEG). Values less than ‘1’ indicates less-than-perfect evasion, such
as other coatings providing decreased evasion capability, or less dense coatings. See
Figure 31 on the following page. PCF is applied against the phagocytosis processes
in the lungs, liver, and spleen.
3.2.4 Surface Charge Eﬀects.
Research suggests that negative or neutrally charged small particles may undergo
higher accumulation in the liver, spleen, or lung [63]. Evidence also suggests that
negative charge on particles leads to increased interaction with the reticuloendothelial
system (i.e., macrophages), thereby reducing the amount excreted in the kidneys [63].
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Figure 31. Phagocytosis coating factor (PCF) (inferred from [18, 20, 49, 72])
Similarly, research suggests that neutral and low concentration anionic (negatively-
charged) nanoparticles can translocate across the BBB, while cationic (positively-
charged) particles do not [54].
In contrast, the kidney glomerular membrane favors positively charged molecules,
which pass through the membrane more easily than uncharged molecules [80, 63].
Note that the glomerulus is both a size- and charge-selective ﬁltration mechanism.
Without additional analysis available describing whether negative or positive charge
is responsible for increased translocation/accumulation, it is hypothesized that zeta
potential (a measure of diﬀerence in charge) is perhaps a more appropriate measure.
Tabata, et al., concluded that surface charge of hydrophilic particles has a great eﬀect
on phagocytosis since particles with large zeta potential (i.e., high charge diﬀerences)
exhibit enhanced phagocytosis [73].
Therefore, a charge-related modiﬁer called the “surface charge factor” (SCF) was
deﬁned, as shown in Figure 32 on the next page. A value of ‘1’ indicates high zeta
potential (i.e., more likely to undergo translocation and cellular uptake in the intra-
cellular space) and ‘0’ indicates low zeta potential (i.e., less likely to undergo uptake
in intracellular space). This modiﬁer aﬀects both the 푇b:t and 푇e:i transfer coeﬃ-
cients, which govern diﬀusion between blood/tissue and extracellular/intracellular,
80
respectively. It also aﬀects the phagocytosis processes.
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Figure 32. Surface charge factor (SCF) (inferred from [63, 54, 80, 73])
81
3.3 Phase III: Deﬁning a New Paradigm for Nano Risk Analysis
“At present, we lack a model to predict hazard or safety just based on the
physicochemical characteristics of new nanomaterials that can be used for
risk assessment or for safe product design.” - G. Oberdo¨rster, et al. [58]
A 2008 North Atlantic Treaty Organization (NATO) workshop to evaluate the
wide-scale implications (both positive and negative) of the use of nanomaterials on
human health and the environment showed that attendees agreed that while existing
chemical risk assessment may provide a starting point, the unique properties of nano-
materials adds considerable complexity to the issue [44]. With the impracticality of
systematically determining individual dose-response curves for nanoparticles of every
material, shape, size, coating, etc., a new paradigm is necessary for nanoparticle risk
assessment.
As diﬀusion, settling, and agglomeration of particles is dependent on particle size,
shape, and charge, so too is cellular dose [74]. Teeguarden et al., describes how the
deﬁnition of dose for nanoparticles is a more dynamic, more complicated, and less
comparable across particle types than it is for soluble chemicals [74]. More research
is necessary to improve understanding on how these physico-chemical characteristics
impacts dose. In addition, mounting evidence that these properties may impact
dose is reason for the scientiﬁc community to consider possibly redeﬁning the term
‘dose’ as it relates to risk assessment. This ‘new paradigm’ would likely deviate
from the commonly used dose metric of mg/kg/day scaling on the x-axis of the dose-
response curve, as it is more than simply the ‘amount’ (i.e., mass or # count, etc.)
of nanomaterials that determines adverse eﬀects (‘response’).
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3.3.1 The Approach.
To begin deﬁning the new paradigm, ﬁrst recognize that risk analysis for nanopar-
ticles is a multi-dimensional problem as nanomaterial dose is likely a function of size,
shape, surface coating, and surface charge due to the recurring emphasis in the liter-
ature. Simulations which include the physico-chemical modiﬁers described in Phase
II of research (Section 3.2 on page 60) are used to calculate the area under the curve
(AUC) for arterial blood concentration vs. time. Arterial blood is an appropriate sub-
compartment to study as it is the source of nanoparticles which ﬂow to the various
organs.
The First Mean Value Theorem for Integration states that the solution to integrat-
ing a function f(t) over an interval [a,b] is f(c)⋅(b-a), where f(c) represents an average
value of f(t) over the interval [82]. In the context of this research, AUC equals the
average concentration in the subcompartment multiplied by length of time. Dividing
average concentration by volume of the subcompartment yields an average amount
in the subcompartment, which is proportional to the dose to the subcompartment.
Therefore, AUC is used as a surrogate of dose (i.e., total nanoparticle exposure to the
subcompartment over a given time period). AUC is in units of concentration⋅time.
Mean Value Theorem for Integration: For all t∈[a, b], there exists c∈(a,
b) such that:
∫ 푏
푎
푓(푡)푑푡 = 푓(푐)(푏− 푎) (25)
Afterwards, a multiple regression (actually, multiple linear regression) is per-
formed on dose as the dependent (criterion) variable, with size, shape, surface coating,
and surface charge as the independent (predictor) variables. Note that the source rate
(i.e., inhalation rate of nanoparticles into the body) was kept constant at 500 (x1000
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particles/liter). Varying the source rate was not part of this research, but increas-
ing or decreasing the source will likely scale the concentration plots, although not
necessarily in a linear manner due to the presence of the nonlinear Michaelis-Menten
saturable processes.
Multiple regression diﬀers from simple linear (bivariate) regression as there is more
than one independent variable involved. It is assumed that all four independent vari-
ables are continuous, not categorical. The result of multiple regression is a regression
equation of the form shown in Equation 26. The regression coeﬃcients, 훽푖, indicate
how the dependent variable, 푌ˆ , changes with each unit of change in an independent
variable, 푥푖 [42].
푌ˆ =훼 + 훽1푥1 + 훽2푥2 + . . .+ 훽푛푥푛 (26)
where
푌ˆ =predicted value of the dependent (criterion) variable
훼 =intercept value (a constant)
훽푖 =multiple regression coeﬃcient, corresponding to variable 푥푖
푥푖 =independent (predictor) variable
Usually ordinary least squares (OLS) or the maximum likelihood method is used
to calculate the regression coeﬃcients. OLS applies to the linear situation only (linear
relationship between dependent and independent variables), while maximum likeli-
hood can be used in either situation [42].
An adequately large sample size (i.e, number of simulations) is necessary so that
the regression equation possesses suﬃcient statistical power to detect a signiﬁcant
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eﬀect. A general rule of thumb frequently cited in research is to use n>50+8⋅m,
where n=sample size and m=# of independent (predictor) variables [24, 83]. For
this research, m=4 which yields a recommended sample size of n>82. As running
additional ‘samples’ for this simulation-based research only adds a few minutes of
computational time when using MATLAB R⃝, a randomized sample size of n=3000
was used.
3.3.1.1 Multiple Regression Assumptions.
Several key assumptions for multiple regression are listed below. Non-linear re-
gression (e.g., logistic regression) is necessary when the linear regression does not
meet these assumptions [42].
∙ A linear relationship between dependent and independent variables.[42]
∙ Normality: each independent (predictor) variable has a normal distribution [42]
∙ Homoscedasticity: variance is constant across all levels of the predicted (depen-
dent or criterion) variable [42], i.e., the same level of relationship throughout the
range of the independent variable
In general, it is possible for the number of independent variables to outnumber
the number of predictors, but in this case, all four independent variables are used
as predictors. Note that for larger sets of independent variables, various methods
exist to identify the most relevant predictor variables that should be included in the
regression equation (e.g., forward selection, backward elimination, stepwise selection)
[42].
3.3.1.2 Speciﬁc Steps for Phase III.
The speciﬁc steps to be followed for Phase III of the research are:
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(1) Random distribution: Use random number generator in MATLAB R⃝ to ran-
domize size, shape, surface coating, and surface charge to develop a list of
simulations
(2) Run these simulations through the MATLAB R⃝ model with diﬀusion in par-
allel with active- and carrier-mediated transport
(3) Calculate concentration vs. time for the arterial blood subcompartment
(4) Calculate AUC, using the trapezoidal rule, over the entire simulation time
(i.e., t=200 hours).
(5) Export size, shape, surface coating, surface charge, and AUC as an .xls ﬁle
for import into SAS JMP R⃝
(6) Perform a multiple linear regression on AUC (i.e., a surrogate of dose or total
exposure) as a function of size, shape, surface coating, and surface charge to
derive the regression equation
(7) Analyze goodness-of-ﬁt and summary statistics
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IV. Results and Analysis
“I have not failed. I’ve just found 10,000 ways that won’t work.”
- Thomas A. Edison
Clearly, improving our understanding of the biokinetics and distribution of nanopar-
ticles in humans is essential to advancing risk assessment for nanoparticle exposures.
The ultimate goal of the dissertation research is to determine one or more broad
conclusions that will provide a signiﬁcant contribution to the nanoparticle risk as-
sessment ﬁeld. This would include any conclusions drawn that would help form a
new paradigm for risk assessment of nanoparticles, such as the impracticality of at-
tempting to derive an all-encompassing set of dose-response curves to cover all types
of nanoparticles, under all exposure scenarios.
Unlike chemicals, which are considered homogeneous for a given formulation,
nanoparticles sharing the same core material (e.g., silver nanoparticles) can be of
countless sizes, shapes, surface charge, surface areas, surface coatings, etc. These
diﬀerences, however subtle, may have signiﬁcant impact on toxicity.
Therefore, it seems obvious that the number of resulting dose-response curves
would be staggering and unrealistic to attempt to gather. For this dissertation, there
were three distinct phases of research: Model Formulation, Inclusion of Physico-
Chemical Properties, and Deﬁning a New Paradigm for Nano Risk Analysis. Results
for the phases will be summarized in the paragraphs to follow.
4.1 Phase I: Model Formulation Results
The full PBPK model that resulted from Phase I is shown in Appendix B on
page 126. This model was used for the range ﬁnding exercise described below and
was also the basis for Phases II and III of the research. A listing of the ODEs that
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comprise the PBPK model is in Appendix C on page 134.
4.1.1 Range Finding Results.
4.1.1.1 Summary of Range Finding Exercise.
Early in the research, it was decided that the most important parameters to focus
range ﬁnding on were 푇b:t, 푇e:i, 푉maxat, 푉maxcmt1, and 푉maxcmt2. These parameters
govern transport between either blood and extracellular (i.e., tissue) or extracellular
and intracellular space. Identifying suitable values for the key transport parameters
in the model which govern cellular transport was the focus, not precision. It should
be noted that the methodology followed does not avoid the need for future laboratory
research on parameterization and perhaps the results presented in the dissertation
underscore the importance of pursuing such research. Table 7 is a summary of the
values selected from the range ﬁnding exercise described in Section 3.1.4 on page 48.
A more detailed discussion of these ﬁndings follows.
Table 7. Range ﬁnding results
Physiological Value Chosen
Parameter Variable (x1000 particles/hour)
Transfer Coeﬃcient,
blood-to-tissue 푇b:t 5
Transfer Coeﬃcient,
extra-to-intracellular 푇e:i 0.05
Active Transport,
Max Rate of Transport 푉maxat 0.5
Carrier Mediated Transport,
Max Rate of Transport1 푉maxcmt1 0.5
Carrier Mediated Transport,
Max Rate of Transport2 푉maxcmt2 0.5
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4.1.1.2 Instantaneous Equilibration Results.
For IE, a single compartment is used to represent the entire organ/tissue group.
Tissue concentration is calculated by dividing the amount of nanoparticles in the
compartment by organ volume. Then, the tissue concentration is divided by the
tissue:blood partition coeﬃcient to determine venous blood concentration. A simpli-
fying assumption used for IE is that the tissue blood volume is considered negligible.
Higher blood ﬂow rates and smaller volumes tend to cause higher concentrations,
with loss mechanisms aﬀecting concentrations also. Figure 33 shows a summary of
instantaneous equilibration. The nanoparticle concentrations in tissue (assuming IE)
for the various organs are shown in Figure 34.
t : b 
tissue
blood
where    P = partition coefficient, tissue-to-blood
             Conc = concentration of analyte in a tissue
             Conc = concentration of analyte in venous blood
Tissue
Blood
tissue
blood
t : b
ConcConc =
P
Figure 33. Instantaneous equilibration model
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Figure 34. Nanoparticle concentrations for IE
The behavior seen in Figure 34, is primarily inﬂuenced by blood ﬂow rates (Q),
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organ volumes (V), and loss mechanisms. The order of the organs from largest to
smallest fraction of cardiac output, 푄frac is: 1) Liver 2) Kidneys 3) RPT 4) GI
5) SPT 6) Brain 7) Spleen. The order from largest to smallest volume is: 1) SPT
2) Liver 3) RPT 4) Brain 5) Kidneys 6) Spleen.
The liver dominates primarily due to its large Q, as it receives inﬂow from both
arterial blood and portal circulation (i.e., GI tract and the spleen). The kidney has
similarly large Q, but much smaller V. This would tend to cause higher concentrations
as concentration ∝ 1/volume, but it has a signiﬁcant loss mechanism to urine which
serves to lower concentrations. The spleen has a very small volume, which leads to
moderately high concentration. RPT and SPT have moderately high concentrations
also, primarily due to the lack of loss mechanisms. Finally, the brain has relatively
low concentration, due to low Q and high V, plus the assumed limiting factor of 10%
transport across the blood-brain barrier.
4.1.1.3 Range Finding for 푇b:t.
As described in Section 3.1.4.1 on page 49, the goal is to ﬁnd a single value of
푇b:t that can be used across all organs. The baseline for the 푇b:t range ﬁnding is
the nanoparticle concentration resulting from an assumption of instantaneous equili-
bration, as shown in Figure 34 on the previous page. Now, the single compartment
representing an organ is split into two subcompartments (tissue and blood), with
diﬀusion inserted between the two subcompartments. See Figure 35.
Blood
Tissue
Diffusion, Blood-to-Tissue
Figure 35. Two-subcompartment model for 푇b:t range-ﬁnding
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Figure 36 on the next page shows the baseline concentrations using IE (black lines)
and the new concentrations as 푇b:t is varied from 0.05 to 50 for each organ. The liver,
spleen, brain, and RPT demonstrate similar behavior, with concentration increasing
as 푇b:t increases. Diﬀerences between the plots are attributable to diﬀerences in
blood ﬂow rates, tissue volumes, and loss mechanisms. Note that the total tissue
concentration is not the arithmetic sum of extra- and intracellular concentrations.
Instead, it equals the sum of the amounts divided by total volume, (amountextra +
amountintra)/(푉extra + 푉intra).
As shown in Figure 36b on the following page, the kidney presents slightly diﬀerent
behavior than the other organs. At 푇b:t ≥0.5, the nanoparticle concentration in
kidney tissue approaches that for IE. This rapid approach to steady state is likely
inﬂuenced by the modeling assumption that a considerable fraction of nanoparticles
goes to urine (20%) and 80% of blood bypasses the glomerular ﬁltration process of the
kidney nephrons. The larger magnitude for kidney concentration is likely due to the
kidney having a relatively small volume (0.3 liters) and concentration ∝ 1/volume.
Slowly perfused tissue also presents diﬀerent behavior. See Figure 36f on the next
page. Concentration in SPT does not rise signiﬁcantly as 푇b:t is increased as seen
in the other organs, due to the extremely large tissue volume (64 liters) which is an
order of magnitude greater than the next largest organ.
After reviewing these plots, it is clear that any value for 푇b:t on the range of 0.5
to 50 keeps the organ concentrations bounded by IE. Therefore, the value chosen for
푇b:t was 5, which keeps four of the six organs approximately midrange between the
upper bound of IE and zero. Figure 37 shows the resulting concentrations for the
organs when 푇b:t=5 is inserted into the model.
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(b) Kidneys
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(c) Spleen
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(d) Brain
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Figure 36. Nanoparticle concentrations for 푇b:t range ﬁnding
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Figure 37. Tissue nanoparticle concentrations for 푇b:t=5
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4.1.1.4 Range Finding for 푇e:i.
Range ﬁnding for 푇e:i is conducted by using the three-subcompartment repre-
sentation shown in Figure 38 with the tissue portion of each organ now split into
extracellular and intracellular subcompartments.
Blood
Extracellular
Diffusion, Blood-to-Tissue
Intracellular
Diffusion, Extra-to-Intra
Figure 38. Three-subcompartment model for 푇e:i range-ﬁnding
The range ﬁnding results showed that the diﬀerent organs all behave similarly
in response to varying 푇e:i over the range 0.05 to 50. Larger values of 푇e:i lead to
a faster approach to steady state. A value of 푇e:i=0.05 was chosen as this best
keeps the resulting tissue concentrations across the organs to within 2× the tissue
concentrations determined using 푇b:t.
The resulting plot of concentrations for the organs when 푇e:i = 0.05 is inserted
into the model is shown in Figure 40.
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Figure 39. Nanoparticle concentrations for 푇e:i range ﬁnding
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Figure 40. Tissue nanoparticle concentrations for 푇e:i=0.05
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4.1.1.5 Range Finding for 푉maxat.
To determine the value for 푉maxat, which is the Michaelis-Menten maximum rate
for active transport between extracellular and intracellular, we use the results from
the 푇e:i range-ﬁnding (i.e., diﬀusion between extra- and intracellular) as the baseline.
This method relies on a three-subcompartment representation for each organ. For
this simulation, active transport and diﬀusion work in parallel between extra- and
intracellular subcompartments as shown in Figure 41.
Blood
Extracellular
Diffusion, Blood-to-Tissue
Intracellular
Active TransportDiffusion
Figure 41. Three-subcompartment model for 푉maxat range-ﬁnding
Figure 42 on the following page shows the baseline of tissue concentrations using
푇e:i (black lines) with new concentrations as 푉maxat is varied from 0.05 to 50 for each
organ. Results indicate that diﬀusion operating in parallel with the uni-directional ac-
tive transport process appears to allow organ concentrations to approach steady state.
Recall that without diﬀusion operating in parallel, there was a limitless buildup of
nanoparticles in the intracellular subcompartment, as no loss/exit mechanism existed
for the intracelllular subcompartment. Such a limitless buildup is not realistic.
The various plots in Figure 42 on the next page indicate that 푉maxat=50 leads to
extremely high concentrations that are an order of magnitude larger than previously
seen. Although diﬀusion is operating in parallel with active transport (between ex-
tracellular and intracellular), it appears that extremely high values for 푉maxat allows
the active transport portion to dominate (overcome) the eﬀects of diﬀusion and much
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higher accumulation in extracellular and intracellular occurs.
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Figure 42. Nanoparticle concentrations for 푉maxat range ﬁnding
A value of 0.5 was chosen as it best keeps 푉maxat within 2× the tissue concentra-
tions using 푇e:i, which is shown as the black line in Figure 42. The resulting plot of
concentrations for the organs when 푉maxat = 0.5 is inserted into the model is shown in
Figure 43. This same value for 푉maxat is used as 푉maxcmt1, as both represent saturable
(Michaelis-Menten) terms in the extracellular-to-intracellular direction.
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Figure 43. Tissue nanoparticle concentrations for 푉maxat=0.5
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4.1.1.6 Range Finding for 푉maxcmt2.
In the previous section (Section 4.1.1.5 on page 95), 푉max for active transport,
which goes from extra- to intracellular, was determined. Carrier mediated transport,
however, is modeled using two sets of Michaelis-Menten constants (extra- to intra-
cellular and intra- to extracellular), as shown in Equation 4 on page 23. The 푉max
determined for active transport is also used as 푉maxcmt1, as both apply to the extra-to-
intracellular direction. Therefore, range-ﬁnding is necessary only for 푉maxcmt2, which
is for the intra-to-extracellular (i.e., reverse) direction.
This method relies on a three-subcompartment representation for each organ, as
shown in Figure 44, with carrier mediated transport and diﬀusion working in parallel
between extra- and intracellular subcompartments.
Blood
Extracellular
Diffusion, Blood-to-Tissue
Intracellular
Carrier Mediated TransportDiffusion
Figure 44. Three-subcompartment model for 푉maxcmt2 range-ﬁnding
Figure 45 on the following page shows the baseline with new concentrations as
푉maxcmt2 is varied from 0.05 to 5 for each organ. The plot behavior is very similar to
that seen during 푉maxat range ﬁnding. A value of 0.5 best keeps 푉maxcmt2 within 2×
the concentrations realized using 푇e:i.
The resulting plot of concentrations for the organs when 푉maxcmt2 = 0.5 is inserted
into the model is shown in Figure 46.
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Figure 45. Nanoparticle concentrations for 푉maxcmt2 range ﬁnding
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Figure 46. Tissue nanoparticle concentrations for 푉maxcmt2=0.5
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4.1.2 Comparison of Plots for Transport Processes.
After completing the range ﬁnding exercise in the previous section, the next step
was to re-run the MATLAB R⃝ model to investigate how assumptions of active trans-
port and carrier mediated transport aﬀect nanoparticle concentrations in the organs,
as compared to the traditional assumption of instantaneous equilibration. Note that
both active- and carrier mediated transport operate between extracellular and in-
tracellular, and both processes are assumed to operate with diﬀusion in parallel, as
shown in Figures 41 on page 95 and 44 on page 98. Figure 47 on the next page shows
the nanoparticle concentrations under various transport assumptions.
Figure 47b shows the concentration curves for the organs when diﬀusion is the
process between extracellular and intracellular. In comparison, Figures 47c, 47d,
and 47e show the concentrations if active+diﬀusion, carrier mediated+diﬀusion, or
active+carrier+diﬀusion had been used. These three plots are nearly identical in
appearance to the diﬀusion-only plot in Figure 47b, which indicates that diﬀusion
likely dominates between extracellular and intracellular. Figure 47e is important
to note, as this represents the ﬁnal model formulation with diﬀusion operating in
parallel with active transport and carrier mediated transport, as shown in Figure 48
on page 102.
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(b) Diﬀusion
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(c) Active + Diﬀusion
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(d) Carrier Med. + Diﬀusion
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(e) Active + Carrier+ Diﬀusion
Figure 47. Nanoparticle concentrations under various transport assumptions
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TransportDiffusion
Active 
Transport
Figure 48. Example: ﬁnal operational concept with diﬀusion in parallel with active and
carrier mediated transport
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4.1.3 Eigenvalue Analysis Results.
Eigenvalue analysis can be used to characterize the behavior of tissues as trans-
port parameters are varied and provide powerful insight on how rapidly nanoparticle
concentrations reach steady state. Large magnitude (negative) eigenvalues indicate
fast buildup and small magnitude eigenvalues indicate slow buildup. As slow buildup
implies slow decay, this may be of toxicological signiﬁcance as this would lengthen
the recovery time necessary between exposures. In the simulations presented here,
eigenvalue analysis allows conclusions deﬁning future research over a small number
of simulations when it would otherwise take many simulations to reach the same
conclusions.
Note that the representation of active- and carrier mediated transport using
Michaelis-Menten kinetics prevents eigenvalue analysis from being conducted as there
are nonlinear terms (i.e., concentration appears also in the denominator). See Equa-
tion 27. A simple solution to linearize the nonlinear Michaelis-Menten terms is to
rewrite the equation into either the ﬁrst order or zero-order approximations shown in
Equation 28 on the following page.
Active Transport Rate =
푉max ⋅ 퐶
퐾m + 퐶
(#particles/hour) (27)
where
푉max = max rate of transport (#particles/hour)
퐶 = concentration (#particles/liter)
퐾m = Michaelis-Menten constant (#particles/liter)
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Active Transport Rate ≈
⎧⎨⎩
푉max ⋅ 퐶
퐾푚
, 퐶 ≪ 퐾푚
푉max, 퐾푚 ≪ 퐶
(28)
For the ﬁrst-order approximation, choosing a slope of 푉max/퐾m is a good ap-
proximation at low concentrations, C≪퐾m, but is a poor approximation at higher
concentrations. A better choice of slope is 푉max/2/퐾m, which is the slope through the
point with coordinates concentration=퐾m and rate=푉max/2, where 퐾m is deﬁned as
the concentration at 푉max/2. See Figure 49. The zero-order approximation is simply
푉max, which is the asymptote for the curve as it approaches steady state.
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Figure 49. Example: ﬁrst-order approximation of Michaelis-Menten kinetics
Figure 50a on the following page shows that linearizing the model using a ﬁrst-
order approximation of 푉max/2/퐾m and a zero-order approximation of 푉max provides
results nearly identical to the nonlinear model shown in Figure 50b. This demon-
strates how a nonlinear model, such as one with Michaelis-Menten saturable processes,
can be linearized in order to enable eigenvalue analysis.
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(a) Linearized model
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(b) Nonlinear model
Figure 50. Comparison of the linearized and non-linear results
4.1.3.1 Eigenvalue Analysis of 푇e:i.
The goal of this portion of the research is to demonstrate the concept of eigen-
value analysis. In the previous section, it was shown that linearizing the model using
zero-order and ﬁrst-order approximations provide results nearly identical to the non-
linear results. This, in theory, allows eigenvalue analysis of the nonlinear model by
linearizing via either of these approximations. However, to demonstrate eigenvalue
analysis 푇e:i was selected.
The matrices shown in Appendix F on page 176 represent the eigenstructure of
the model as the transfer coeﬃcient 푇e:i is varied. An index showing which rows
correspond with each subcompartment is shown in Figure 81 on page 176. Each
eigenstructure matrix has the eigenvalues listed in the top row above their associated
eigenvectors. The columns have been sorted with the largest magnitude eigenvalues
to the left side of the matrix. In the matrices that follow, any small terms in the
eigenvectors (< 0.05) are shown as ’0’. Each eigenvector was then normalized to the
1-norm format (L1-norm), where the sum of absolute values of the terms equals 1.
This allows us to see the fractional contributions of speciﬁc organs to the various time
scales (decay rates), represented by the eigenvalues, 휆.
It was previously stated that eigenvalues can be linked to speciﬁc subcompart-
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ments. Doing so can be challenging, as a given subcompartment can contribute to
multiple time scales (eigenvalues) which is indicated by more than one non-zero en-
try in a given row of the eigenstructure. In addition, contributions to a single time
scale (eigenvalue) from diﬀerent subcompartments can change as a parameter is var-
ied. Because of these phenomena, it is necessary to study the set of eigenstructures
as a parameter is varied, in order to deduce which eigenvalue corresponds to which
subcompartment.
As a parameter is varied, some subcompartments display changes in their eigenval-
ues. Others may have relatively steady eigenvalues. A display of such behavior can be
seen in Figure 51 on the next page. It is important to note that these plots are log-log
scale, so sloped lines indicate rapidly (i.e., exponentially) changing eigenvalues.
Figure 51 shows that the blood subcompartments of the various organs (blue lines)
show a rapid approach to steady state, as indicated by the large magnitude (nega-
tive) eigenvalues. The eigenvalues for the blood subcompartments remain relatively
constant as the transport parameter 푇e:i is varied through the range 0.005 to 0.5.
The extracellular subcompartments (green lines) show downward sloping behavior at
the higher values of 푇e:i, indicating a faster approach to steady state. Intracellular
subcompartments (red lines) appear to respond to changes in eigenvalue behavior
for extracellular. One conclusion that could be made is that ﬁne-tuning the value of
the diﬀusion transfer coeﬃcient may be important, as eigenvalues can change greatly
depending on 푇e:i, which can lead to widely varying concentration results.
In Figure 52 on the following page, the eigenvalues for the lungs and GI tract
subcompartments are unresponsive to variations in the transport parameter 푇e:i over
the range 0.005 to 0.5. This indicates that pursuing precise values for 푇e:i will likely
not aﬀect behavior signiﬁcantly in the lungs and GI tract and eﬀorts may be better
spent ﬁne-tuning other transport parameters to further examine those organs.
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Figure 51. Eigenplots for the various organs
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Figure 52. Eigenplots for the lungs and GI tract
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4.2 Phase II: Physico-Chemical Properties Results
4.2.1 Final Transport Equations.
Shown below are the key transport equations with the physico-chemical modiﬁers
inserted. The MATLAB R⃝ code was modiﬁed to include these equations.
B:T Diﬀusion Rate = (PTEF + TEF) ⋅ SCF ⋅ CUSF ⋅ 푇b:t ⋅
(
퐶blood − 퐶extra
푃t:b
)
(29)
Liver Diﬀusion Rate = (LAF + TEF) ⋅ SCF ⋅ CUSF ⋅ 푇b:t ⋅
(
퐶blood − 퐶extra
푃t:b
)
(30)
Spleen Diﬀusion Rate = (SPAF + TEF) ⋅ SCF ⋅ CUSF ⋅ 푇b:t ⋅
(
퐶blood − 퐶extra
푃t:b
)
(31)
Brain Diﬀusion Rate = (BPEF + TEF) ⋅ SCF ⋅ CUSF ⋅ 푇b:t ⋅
(
퐶blood − 퐶extra
푃t:b
)
(32)
E:I Diﬀusion Rate = (CUEF ⋅ CUSF ⋅ SCF) ⋅ 푇b:t ⋅
(
퐶blood − 퐶extra
푃t:b
)
(33)
Active Transport Rate = CUEF ⋅ CUSF ⋅ 푉maxat ⋅ 퐶extra
퐾m + 퐶extra
(34)
Carrier Mediated Rate = CUEF ⋅ CUSF ⋅
(
푉maxcmt1 ⋅ 퐶extra
퐾mcmt1 + 퐶extra
− 푉maxcmt2 ⋅ 퐶intra
퐾mcmt2 + 퐶intra
)
(35)
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where
PTEF = paracellular transport eﬃciency factor (unitless)
TEF = transcytosis eﬃciency factor (unitless)
SCF = surface charge factor (unitless)
CUSF = cellular uptake shape factor (unitless)
LAF = liver accumulation factor (unitless)
SPAF = spleen accumulation factor (unitless)
BPEF = brain paracellular eﬃciency factor (unitless)
CUEF = cellular uptake eﬃciency factor (unitless)
푇b:t = transfer coeﬃcient, blood-to-tissue (liters/hour)
퐶blood = concentration in blood (#particles/liter)
퐶extra = concentration in extracellular (#particles/liter)
푃t:b = partition coeﬃcent from tissue-to-blood (unitless)
푉max = max rate of transport (#particles/hour)
퐾m = Michaelis-Menten constant (#particles/liter)
Besides the transport equations listed above, the three locations of phagocytosis
(i.e., lungs, liver, and spleen) also are aﬀected by the addition of physico-chemical
properties. Speciﬁcally, PCF and SCF are multiplied to the ﬁrst-order rate constant
to determine the surface coating- and charge-dependent rate of phagocytosis, as shown
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in Equations 36, 37, and 38.
Lung Phagocytosis Rate =(AM rate const ⋅ 퐶) ⋅ PSF ⋅ PCF ⋅ SCF (36)
Liver Phagocytosis Rate =(phagocytosis rate const ⋅ 퐶) ⋅ PSF ⋅ PCF ⋅ SCF (37)
Spleen Phagocytosis Rate =(phagocytosis rate const ⋅ 퐶) ⋅ PSF ⋅ PCF ⋅ SCF (38)
where
AM =alveolar macrophage
퐶 =concentration (#particles/liter)
PSF =phagocytosis size factor
PCF =phagocytosis coating factor
SCF =surface charge factor
4.2.2 Physico-Chemical Simulations.
Using the MATLAB R⃝ code which contains the modiﬁed transport equations that
account for the physico-chemical properties, a set of simulations was conducted in
order to calculate concentration vs. time and to support Phase III New Paradigm as
discussed in Section 3.3.1 on page 83. 3000 simulations were conducted, with each
simulation consisting of a combination of randomly-generated sizes, shapes, surface
coatings, and surface charges using the ranges shown in Table 8 on the following page.
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Table 8. Phase III physico-chemical properties simulations
Physico-Chemical
Property Range Notes
extended beyond engineered
Size 0 - 500 nm nanoparticle range of <100 nm
Shape 0 - 1 ‘1’= spherical
Surface Coating 0 - 1 ‘1’= ideal coating
Surface Charge 0 - 1 ‘1’= high zeta potential
Using MATLAB R⃝, area under the curve (AUC) was calculated for the arterial
blood concentration after each simulation. A scatter plot showing area under the arte-
rial blood concentration curve for each of the 3000 simulations is shown in Figure 53.
Note that the majority of data points occur at area under the curve<100 (x1000
particles/liter×hours), with occasional values exceeding 600 (x1000 particles/liter×hours).
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Figure 53. Scatter plot showing area under the curve (AUC) for the simulations
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4.3 Phase III: New Paradigm Results
4.3.1 Multiple Regression Analysis.
After exporting the data to JMP R⃝, a regression equation was determined and
is shown in Equation 39. Following the nomenclature described in Equation 26 on
page 84, 훼=101.32 is the intercept value and represents the predicted area under the
arterial blood concentration curve when the independent variables are equal to zero.
The 훽 (regression) coeﬃcients (rounded to -0.15, -10.87, +4.18, -2.74) represent the
contributions of each independent parameter (size, shape, surface coating, surface
charge, respectively) towards the predicted area under the curve. For example, 훽1=-
0.15 implies that a one-unit increase in ‘size’ is associated with a 0.15 decrease in area
under the curve for arterial blood.
AUC = 101.32− 0.15 ⋅ (size)− 10.87 ⋅ (shape) + 4.18 ⋅ (surface coating)
− 2.74 ⋅ (surface charge) (39)
where
AUC = predicted area under the curve (#particles/liter ⋅ hours)
size = nanoparticle size (range 0-500 nm)
shape = particle shape factor (range 0-1, unitless)
surface coating = surface coating factor (range 0-1, unitless)
surface charge = surface charge factor (range 0-1, unitless)
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4.3.1.1 Goodness of Fit.
Diagnostic tests were run using the SAS JMP R⃝ statistical software to check the
goodness of ﬁt of the regression model to actual data. An 푅2=0.092 indicates that
only a very small portion of the variation of area under the arterial blood concentra-
tion curve (9.2%) is explained by variation in the independent variables [17]. A low
푅2 implies that the model is poor at predicting the outcome variable, which is area
under the arterial blood concentration curve. Clearly, using a linear regression model
does not provide the best ﬁt.
To further investigate the ﬁtted equation, Figure 54 shows two diﬀerent perspec-
tives of a 3-dimensional scatter plot showing area under the curve, as size and shape
are varied. Results indicate that area under the arterial blood concentration curve
is dependent primarily on size, as indicated by the L-shaped behavior in Figure 54b.
Shape has minimal inﬂuence on behavior as it simply extends the L-shaped behavior
in the y-direction (i.e., “into the paper”), as shown in Figure 54a.
(a) Perspective #1 (b) Perspective #2
Figure 54. 3-d scatterplot of AUC vs. size vs. shape
This same size-only dependency (i.e., L-shaped behavior) can be seen when surface
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coating and surface charge are substituted for shape and become the y-axis variable
(“into the paper”) as shown in Figure 55. In Section 3.3.1 on page 83, an assumption
of linearity was stated as a necessary condition for linear regression, but performing
the bivariate scatter plots for each of the independent variables versus the dependent
variable reveals that curvature (non-linearity) occurs for area under the curve vs. size.
See Figure 54 on the preceding page and Figure 55. Therefore, the assumption of
linearity is incorrect.
(a) AUC vs. size vs. surface coating (b) AUC vs. size vs. surface charge
Figure 55. 3-d scatterplot of AUC vs. size vs. surface coating and surface charge
To understand why area under the arterial blood concentration curve is mainly
a function of size, recall that the majority of physico-chemical modiﬁers were size-
related and were distributed in numerous sites in the PBPK model. For example,
size determines lung deposition, interstitial translocation, and is critical to all the
transport processes, etc. Shape is also prevalent, whereas surface coating and charge
are not. In fact, surface coating is only a factor for the three sites of phagocytosis.
In Figure 56 on the following page, the actual size vs. area under the arterial blood
concentration curve is plotted in blue with the multiple linear regression equation
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(Equation 39 on page 112) shown in red. This plot clearly shows that trying to a
straight line to the L-shaped curve is problematic and led to the low 푅2 for goodness-
of-ﬁt.
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Figure 56. Plot of the regression equation vs. actual data
4.3.1.2 Statistical Signiﬁcance.
Figure 57 on the following page shows the estimates for the coeﬃcients of the
regression equation shown in Equation 39 on page 112. It also summarizes the sta-
tistical signiﬁcance information for the model, which can be checked using an F-test
for overall ﬁt and additional t-tests for testing the hypotheses about the individ-
ual parameters [17]. The F value of 76.08 is used to test the null hypothesis 퐻표:
훽1=훽2=훽3=훽4=0. The p-value, <0.0001, leads to the rejection of the null hypothesis,
indicating that at least one of the regression coeﬃcients is not zero [17].
The t-statistic for each independent variable compares the ﬁt of the full model with
all four independent variables to the reduced model with the independent variable
corresponding to the t-statistic removed. The t-statistic for size in Figure 57 on the
following page is -17.27, which is for testing the null hypothesis 퐻표: 훽1=0 (i.e., there
is no eﬀect due to size) to compare the full- vs. reduced model. It helps show whether
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the full model (4 independent variables) ﬁts the data better than the reduced model
(3 independent variables) [17].
In this case, the p-value for the test is < 0.0001 and the null hypothesis is rejected
(based on a signiﬁcance level 훼=0.05), indicating that there likely is variation in
area under the arterial blood concentration curve due to size that is not due to
shape, surface coating, or surface charge. The p-value for shape also shows statistical
signiﬁcance for a signiﬁcance level of 훼=0.05. This indicates that there likely is
variation in area under the arterial blood concentration curve due to shape that is
not due to size, surface coating, or surface charge.
In comparison, the p-values for surface coating and surface charge do not allow
rejection of the null hypothesis and we cannot conclude whether variations in area
under the curve for arterial blood concentration are due to the independent variable
exclusively, or due to the other three independent variables.
Parameter Estimates 
Term   Estimate Std Error t Ratio Prob>|t| 
Intercept  101.31779 4.419275 22.93 <.0001* 
size  -0.146723 0.008496 -17.27 <.0001* 
shape  -10.86543 4.226406 -2.57 0.0102* 
surface coating  4.1789123 4.228018 0.99 0.3230 
surface charge  -2.738099 4.282392 -0.64 0.5226 
 
Figure 57. Parameter estimates for n=3000 simulations
4.3.2 An Alternative to Linear Regression.
As Figure 56 on the previous page and the low 푅2 indicate the poor ﬁt of the
multiple linear regression model to actual data, an alternative to linear regression is
necessary. Deriving a nonlinear regression model is more challenging as an approxi-
mate form of the regression equation must be identiﬁed. In Figure 54b on page 113,
the left side of the L-shaped plot shows signiﬁcant decrease in the area under the
arterial blood concentration curve as size increases. At larger sizes, the area under
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the curve increases in a near-linear manner.
After experimentation with numerous forms, an equation of the form 푦 = 푎 −
푏 log(size) + size/푐 was ﬁnally identiﬁed as being a likely good ﬁt for the area under
the arterial blood concentration curve vs. size data. This equation was used in the
MATLAB R⃝ function nlinﬁt to determine the coeﬃcients. The ﬁrst two terms of the
equation help deﬁne the steeply downward sloping portion to the left side of the plot,
while the third term provides the linear, upward-sloping behavior seen to the right
side of the plot. See Figure 58. An 푅2 of 0.943 was realized, indicating a relatively
good ﬁt between actual area under the arterial blood concentration curve data and
the ﬁtted equation.
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Figure 58. Fitted equation
The equation displayed in Figure 58 provides a tool to estimate the area under
the arterial blood concentration curve, which is a surrogate of dose for a given com-
partment. Note that this equation applies to the exposure scenario of 퐶inhalation=500
(×1000 particles/liter). In this research, the equation was determined for arterial
blood and analysis in Section 4.3.1.1 determined that size was the critical factor. For
the model used in this research, the other physico-chemical properties (i.e., shape, sur-
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face coating, and surface charge) can be eliminated as independent variables aﬀecting
the area under the arterial blood concentration curve. Other subcompartments can
be analyzed instead, but arterial blood was chosen as it is central to the distribution
of nanoparticles throughout the body.
4.3.2.1 Relating Area Under the Curve to Risk.
The current paradigm for risk analysis involves the use of in vivo testing, in which
animals such as rats are exposed to external doses of a given chemical. Internal
dose and the resulting adverse response (e.g., cell death, percent responding, etc.) at
speciﬁc target tissues can be measured. This is repeated at various dosages, yielding
a dose-response curve which can be used to assess risk for a given exposure scenario
and to assist in establishing exposure limits based on risk.
In addition, a PBPK model can be created to simulate exactly what happened to
the rat, thus recreating the external-to-internal dose relationship determined from in
vivo research. Such models are useful for studying the time-course behavior of the
chemical. PBPK models can also be used to extrapolate from high to low external
dose and from animal to human.
For nanoparticle risk analysis, the PBPK model presented in this research can be
allometrically-scaled for the rat to recreate in vivo results. Running the rat-speciﬁc
PBPK model will generate concentration plots from which area under the curve can
be calculated. Assuming that area under the curve for the rat equals area under
the curve for the human, and the toxicological responses are the same, the human-
speciﬁc version of this model can be used to determine the external exposure to the
human, by working backwards from area under the curve. More speciﬁcally, once
area under the curve is known then concentration can be determined as area under
the curve∝concentration×time. The source term (i.e., external exposure) can be
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determined since
푐⃗ss = −퐴−1푠⃗⇒ 푠⃗ = −퐴푐⃗ss (40)
The results of this research is the deﬁning of a new paradigm in which we use
the traditional methodology of in vitro and in vivo research combined with PBPK
modeling, but use area under the curve as surrogate of dose which bridges rat to
human. By bridging, the dose-response curves speciﬁc to the animal can be used to
establish equivalent human dose-response curves. More importantly, we can use area
under the curve and the mathematics presented here to back-calculate and ﬁnd the
external exposure to the human which generates an equivalent response to that seen
in the animal. Knowing these external exposure values then assists toxicologists and
policy makers in assessing risk and setting appropriate exposure limits.
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V. Conclusion
“A better understanding is needed about the interplay of factors contributing and
aﬀecting uptake and disposition from deposits in the respiratory tract or from
other portals of entry.” - Gu¨nter Oberdo¨rster, et al. [58]
This work here begins the exploration of mathematical representations of cellular
transport processes and how they may provide insight for nanoparticle exposures.
Using the traditional assumption of instantaneous equilibration can provide vastly
diﬀerent nanoparticle concentrations when compared to other transport processes.
It is important that future research focus on further exploring which transport pro-
cesses are applicable to nanoparticles and determining appropriate values or ranges
for transport parameters governing nanoparticle pharmacokinetics. Further reﬁne-
ment of the mathematical representations of the cellular transport processes will help
improve the predictive ability of the model.
Physico-chemical property-related phenomena of nanoparticles cause considerable
diﬀerences in the biokinetics. Engineering the particles to take on certain qualities
(e.g., size, shape, surface coatings, surface charge) can help defeat, whether intention-
ally or unintentionally, various tissue barriers and loss mechanisms (e.g., phagocyto-
sis). Reﬁning the model to include these qualities is important and in vitro and in
vivo research are critical to improving this PBPK model, which is perhaps the ﬁrst
of its kind to extensively explore the alternate transport processes.
Redeﬁning nanoparticle risk assessment is not simply important, rather it is nec-
essary. The current methodology of performing toxicity testing on each possible
variant of nanoparticles is impractical and perhaps impossible as new variants oc-
cur daily and quality control challenges with producing homogeneous nanoparticles
suggest that toxicity may change depending on the batch.
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5.1 Addressing the Research Questions
Section 1.2 on page 2 listed three research questions fundamental to this disserta-
tion. The following is a synopsis of the ﬁndings related to those questions:
∙ Question #1: For nanoparticle PBPK modeling, what are the implica-
tions of these diﬀerent processes on tissue concentrations, as compared
to an assumption of instantaneous equilibration? Section 4.1 on page 87
shows that deviating from the traditional assumption of instantaneous equilibra-
tion leads to very diﬀerent concentrations. Instantaneous equilibration relies on
ﬁrst calculating tissue concentrations, from which venous blood concentrations are
calculated using a partition coeﬃcient. By inserting mathematical representations
for diﬀusion, active transport, and carrier mediated transport (and by expand-
ing to three subcompartments per organ), we see various behaviors emerge. Such
behaviors include delays to approach steady state, tissue accumulation, and the
dominance of diﬀusion. Although more research is necessary on the applicability
of active transport, it is evident that it could lead to considerable accumulation in
tissue as it operates, by deﬁnition, independent of concentration. Simply expanding
the model to three subcompartments per organ, allowed more accurate placement
of loss mechanisms such as phagocytosis, urine, etc.
∙ Question #2: How can these implications guide the direction of nanotox-
icity research, particularly in determining parameter values for transport
processes elucidated to be important? Section 4.1 on page 87 shows the dif-
ferences in concentrations presented when the transport processes are changed.
The range ﬁnding technique described in this research was critical to the subse-
quent phases of research that followed it, but does not replace future research on
parameterization. The eigenvalue analysis technique provides a new tool for the
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nanotoxicity community, which can provide a rapid summary of model behavior
using a small set of simulations. It can narrow the range of concern for a certain
parameter or perhaps identify parameters which do not signiﬁcantly aﬀect con-
centrations in organs, thus avoiding unnecessary research. The physico-chemical
modiﬁers were an important ﬁrst step in deﬁning size/shape/surface-speciﬁc trans-
port behavior, which often varies organ-to-organ. More research is necessary to
identify a more complete set of variables that aﬀect dose to the organ. More re-
search is necessary on how these physico-chemical properties interact with each
other, e.g., how do special coatings extend the size range of nanoparticles that can
cross a tissue barrier, etc.
∙ Question #3: How will these ﬁndings suggest a possible new paradigm
for nanoparticle risk analysis, particularly in the area of dose-response
assessment? PBPK is beneﬁcial as it can estimate internal dose given an ex-
ternal dose, but the approach presented here improves on that capability, due to
inclusion of physico-chemical properties. Section 4.3 on page 112 shows that there
is strong reason to believe that size truly is the most important physico-chemical
property that aﬀects the biokinetics of nanoparticles. By ﬁtting an equation, AUC
can be estimated at various toxic endpoints based on knowledge of nanoparticle
size only. Toxicologists have already performed, and continue to perform, exten-
sive in vitro and in vivo research on nanoparticle exposures. Their knowledge of
which tissues show considerable adverse response, when combined with simulation
modeling that can help estimate dose to the organ, could oﬀer a better alternative
than the current risk assessment tools available to occupational health practition-
ers. The new paradigm established by this research allows traditional in vitro, in
vivo, and PBPK modeling to be used, but substitutes area under the curve as a
surrogate of dose. By doing so, animal testing results can be bridged to the hu-
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man, after which the corresponding external exposure to the human necessary to
generate the toxicological response can be calculated. This new paradigm allows
toxicologists and policymakers to then assess risk to a given exposure and assist in
setting appropriate exposure limits for nanoparticles.
5.2 Recommendations for the Future
Without question, nanotechnology will have a considerable impact on the world,
primarily from a consumer standpoint and likely from a health and environmental
perspective, also. The burgeoning ﬁeld of nanotoxicology will undoubtedly continue
to grow as the prevalence of nanomaterials grows, as it is clear that nano-sized par-
ticles present new exposure risks not seen by larger particles of the same material.
Research needs to build on the foundation set by ultraﬁne particle research, but
clearly more information is needed in order to properly conduct risk assessment on
nanoparticle exposures. Comprehensive modeling of exposure levels to humans is
necessary, especially in the absence of exposure limits and guidelines.
In closing, there are several ideas on how the PBPK model can be further im-
proved, in order to advance the capabilities to estimate dose and assess risk due to
nanoparticle exposures:
∙ Use the new paradigm as a potential screening strategy and reﬁne it as in vitro
and in vivo research evolve.
∙ Add the lymph system as it is the parallel transport system to blood circulation.
Phagocytosis is not an elimination process. Instead, include the dynamics asso-
ciated with macrophage populations (i.e, any capacity limits, eﬀective life, etc.).
Lymph nodes might also be toxicological endpoints and lymph re-enters circulation.
∙ Expand the lung model to include variations in deposition and transport which
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depart from assumptions of uniformity.
∙ Expand the kidney portion of the model to include the complexities associated with
secretion and reabsorption.
∙ Expand the ingestion route of entry to address whether nanoparticles entrapped in
swallowed ﬂuid can actually be re-entrained and enter circulation via the GI tract
and portal circulation
∙ Coagulation and agglomeration should be addressed. An assumption of monodis-
perse, singlet particles may overstate organ exposure and accumulation.
∙ Qualitative factors for shape, surface coatings, and surface charge need thorough
research.
∙ Exploit data from pharmaceutical research, such as the extensive work on targeting
the brain and defeating the blood-brain barrier to treat brain-related diseases. Such
pharmaceutical insight can guide toxicological research.
∙ Reﬁne the mathematical representations of transport processes by calibrating to in
vitro and in vivo results, as they become available.
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Appendix A. Research Assumptions
General assumptions used for the dissertation research:
Model should focus on inhalational exposures. However, ingestion will be in-
cluded with respect to swallowing of nanoparticles cleared from the respiratory tract
by the mucociliary escalator. Literature does not support dermal exposures as be-
ing a conﬁrmed, major exposure pathway, and therefore it will not be covered in
dissertation research.
Deposition of particles in the respiratory tract will include simplifying assump-
tions that deposition and subsequent absorption/clearance is uniform within a given
region of the respiratory tract (i.e., nasopharyngeal, tracheobronchial, and alveo-
lar). More complex deposition models exist, but are not of primary importance
for this dissertation as general behavior, not precise concentrations, are the focus.
Alveolar deposition will be the primary focus, but nasopharyngeal deposition will
be included as part of the nose-to-brain translocation pathway. The overloading
phenomena which leads to possible interstitial translocation is not included in the
model.
Translocation between the alveolar and interstitial regions of the lungs is
a critical part of this model and most likely warrants expanding the lung compart-
ment accordingly. A major diﬀerence between traditional particle toxicology and
nanoparticle toxicology is this interstitial translocation capability.
Inhalational pathway does not include modeling of the nose-to-brain translocation
pathway, which is separate from the BBB translocation pathway. Even if it results
in a minor exposure pathway, nose-to-brain translocation is of considerable interest
to the pharmaceutical industry, especially regarding administration of drugs for
treatment of brain-related diseases (e.g., Parkinson’s, Alzheimer’s, etc.).
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Appendix B. Full PBPK Model in STELLA R⃝
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Figure 59. Lung representation in STELLA R⃝
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(b) Expanded model
Figure 60. Liver representation in STELLA R⃝
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(b) Expanded model
Figure 61. Kidney representation in STELLA R⃝
128
Qspleen Ca
Aspleen
u7
Arterial to SpleenTo Liver1
Cvspleen
P
Cspleen
tissue1
Vspleen
Phagocytosis
 Coeff
Spleen 
Phagocytosis
Spleen Instantaneous Equilibrium
- 9 -
(a) Instantaneous equilibration
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(b) Expanded model
Figure 62. Spleen representation in STELLA R⃝
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(b) Expanded model
Figure 63. Brain representation in STELLA R⃝
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(b) Expanded model
Figure 64. Richly perfused tissue representation in STELLA R⃝
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(b) Expanded model
Figure 65. Slowly perfused tissue representation in STELLA R⃝
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Figure 66. GI tract representation in STELLA R⃝
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Appendix C. Model Ordinary Diﬀerential Equations (ODEs)
Lung ODEs
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Figure 67. Lung model in STELLA R⃝
d(Alveolar Air u16)
d푡
=(To alveolar region - Alveolar region deposition
- Exhalation) (41)
where
To alveolar region = Qresp× Cinh× Fraction reaching gas exchange
Alveolar region deposition = Qpulm× Calv× Fraction deposited in alveolar region
Exhalation = Qpulm× Calv× Fraction exhaled
Calv = Alveolar Air u16/Valv
Fraction exhaled = 1− Fraction deposited in alveolar region
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Fraction reaching gas exchange = 1− Fraction deposited in upper airways
d(Alveolar Blood u18)
d푡
=Translocation + From venous− To arterial (42)
where
Translocation = Translocation rate× SAConc− ConcAlvBl/Pbl2dep
From venous = Qc× Cv
To arterial = Qc× Ca
ConcAlvBl = Alveolar Blood u18/Valvbl
Ca = ConcAlvBl
SAConc = Alveolar surface u17/SA
d(Alveolar surface u17)
d푡
=Alveolar region deposition - Translocation
- Alveolar macrophage phagocytosis (43)
where
Alveolar region deposition =Qpulm× Calv× Fraction deposited in alveolar region
Translocation =Translocation rate× (SAConc - ConcAlvBl/Pbl2dep)
Alveolar macrophage phagocytosis =Alveolar surface u17× AM Rate
d(Mucosa u15)
d푡
=Deposition in upper airways - To GI (44)
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where
Deposition in upper airways = Qresp× Cinh× Fraction deposited in upper airways
To GI = Surface Area Concentration×Mucus Transport Velocity
× Trachea Perimeter
Surface Area Concentration = Mucosa u15 / Tracheobronchial Surface Area
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Liver ODEs
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(a) Liver IE
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(b) Liver expanded
Figure 68. Liver IE and expanded models in STELLA R⃝
Liver IE.
d(Aliver u1)
d푡
=From GI + Arterial to Liver + From Spleen
- Liver to Venous - Phagocytosis Removal - To Bile (45)
where
From GI = To Liver
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Arterial to Liver = Qliver× Ca
From Spleen = To Liver from Spleen
Liver to Venous = (Qliver + Qportal)× Cvliver
Phagocytosis Removal = Aliver u1× Phagocytosis Coeﬀ
To Bile1 = Aliver u1× Bile Factor
Clivertissue1 = Aliver u1 / Vliver
Cvliver = Clivertissue1 / P
To Liver from Spleen = To Liver1 + To Liver2
Liver (Expanded).
d(Ablood u1)
d푡
=From Arterial + From GI2 + From Spleen1
- To Venous - Diﬀ Fluxb2t (46)
where
From Arterial = Qliver× Ca
From GI2 = To Liver
From Spleen1 = To Liver from Spleen
To Venous = (Qliver + Qportal)× Cvl
Diﬀ Fluxb2t = TransferCoeﬀbloodtissue× (Cvl - Cextra/Ptissue2blood)
Cvl = Ablood u1/Vbloodliver
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d(Aextracellular u2)
d푡
=Diﬀ Fluxb2t - Carrier Mediated - Diﬀ Fluxe2i
- Active Transp - To Bile2 - Phagocytosis Removal2
(47)
where
Diﬀ Fluxb2t = TransferCoeﬀbloodtissue× (Cvl - Cextra/Ptissue2blood)
Carrier Mediated = Vmaxe2i× Cextra/(Kme2i + Cextra)
- Vmaxi2e× (Cintra/Pintra2extra)/(Kmi2e + Cintra/Pintra2extra)
Diﬀ Fluxe2i = TransferCoeﬀextra2intra× (Cextra - Cintra/Pintra2extra)
Active Transp = Vmaxe2i× Cextra / (Kme2i + Cextra)
To Bile2 = Bile Factor× Aextracellular u2
Phagocytosis Removal2 = Aextracellular u2× Phagocytosis Coeﬀ
Cextra = Aextracellular u2/ Vextraliver
Cintra = Aintracellular u3 /Vintraliver
d(Aintracellular u3)
d푡
=Carrier Mediated + Diﬀ Fluxe2i + Active Transp (48)
where
Carrier Mediated = Vmaxe2i× Cextra/(Kme2i + Cextra) - Vmaxi2e
× (Cintra/Pintra2extra)/(Kmi2e + Cintra/Pintra2extra)
Diﬀ Fluxe2i = TransferCoeﬀextra2intra× (Cextra - Cintra/Pintra2extra)
Active Transp = Vmaxe2i× Cextra / (Kme2i + Cextra)
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GI ODEs
Qgi
+
To Bile
GI Blood
u19
GI Lumen
u20
Feces Rate
From mucociliary 
escalator
GI diffusion
Arterial to GI
Ca
To Liver
Tgi
Pbl2lumen
Cgiblood
Vgiblood
ClumenVlumen From Liver 
Bile
To GI
Loss to Feces
GI Tract
- 17 -
Figure 69. GI model in STELLA R⃝
d(GI Blood u19)
d푡
=Arterial to GI + GI diﬀusion - To Liver (49)
where
Arterial to GI = Qgi× Ca
GI diﬀusion = Tgi× (Clumen - Cgiblood/ Pbl2lumen)
To Liver = Qgi× Cgiblood
Cgiblood = GI Blood u19 / Vgiblood
Clumen = GI Lumen u20 / Vlumen
d(GI Lumen u20)
d푡
=From mucociliary escalator + From Liver Bile
- Loss to Feces - GI diﬀusion (50)
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where
From mucociliary escalator = To GI
From Liver Bile = To Bile
Loss to Feces = GI Lumen u20× Feces Rate
GI diﬀusion = Tgi× (Clumen - Cgiblood/ Pbl2lumen)
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Figure 70. Kidney IE and expanded models in STELLA R⃝
Kidney IE.
Glomerular Filtration =GF Rate×Qkidney× Ca (51a)
d(Akidney u4)
d푡
=Arterial to Kidney - Kidney to Venous (51b)
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where
Arterial to Kidney = Bypass Rate×Qkidney× Ca
Kidney to Venous = Qkidney× Cvkidney
Ckidneytissue1 = Akidney u4 / Vkidney
Cvkidney = Ckidneytissue1 / P
Kidney (Expanded).
Glomerular Filtration2 =Qkidney× Ca×GF Rate (52a)
d(Ablood 2 u4)
d푡
=From Arterial 2 - To Venous 2 - Diﬀ Fluxb2t 2 (52b)
where
From Arterial 2 =Qkidney× Ca× Bypass Rate
To Venous 2 =Qkidney× Cvk
Diﬀ Fluxb2t 2 =TransferCoeﬀbloodtissue× (Cvk - Cextra 2/Ptissue2blood)
Bypass Rate =1 - GF Rate
Cvk =Ablood 2 u4/ Vbloodkidney
d(Aextracellular 2 u5)
d푡
=Diﬀ Fluxb2t 2 - Carrier Mediated 2
- Diﬀ Fluxe2i 2 - Active Transp 2 (53)
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where
Diﬀ Fluxb2t 2 =TransferCoeﬀbloodtissue× (Cvk - Cextra 2/Ptissue2blood)
Carrier Mediated 2 =Vmaxe2i× Cextra 2/(Kme2i + Cextra 2)
- Vmaxi2e× (Cintra 2/Pintra2extra)/(Kmi2e + Cintra 2/Pintra2extra)
Diﬀ Fluxe2i 2 =TransferCoeﬀextra2intra× (Cextra 2 - Cintra 2/Pintra2extra)
Active Transp 2 =Vmaxe2i× Cextra 2 / (Kme2i + Cextra 2)
Cextra 2 =Aextracellular 2 u5/ Vextrakidney
Cintra 2 =Aintracellular 2 u6 / Vintrakidney
d(Aintracellular 2 u6)
d푡
=Carrier Mediated 2 + Diﬀ Fluxe2i 2 + Active Transp 2
(54)
where
Carrier Mediated 2 = Vmaxe2i× Cextra 2/(Kme2i + Cextra 2)
- (Vmaxi2e×(Cintra 2/Pintra2extra)/(Kmi2e + Cintra 2/Pintra2extra)
Diﬀ Fluxe2i 2 = TransferCoeﬀextra2intra× (Cextra 2 - Cintra 2/Pintra2extra)
Active Transp 2 = Vmaxe2i× Cextra 2 / (Kme2i + Cextra 2)
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Figure 71. Spleen IE and expanded models in STELLA R⃝
Spleen IE.
d(Aspleen u7)
d푡
=Arterial to Spleen - To Liver1 - Spleen Phagocytosis (55)
where
Arterial to Spleen = Qspleen× Ca
To Liver1 = Qspleen× Cvspleen
Spleen Phagocytosis = Aspleen u7× Phagocytosis Coeﬀ
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Cspleen tissue1 = Aspleen u7 / Vspleen
Cvspleen = Cspleen tissue1 / P
Spleen (Expanded).
d(Ablood 3 u7)
d푡
=From Arterial 3 - To Liver2 - Diﬀ Fluxb2t 3 (56)
where
From Arterial 3 = Qspleen× Ca
To Liver2 = Qspleen× Cvs
Diﬀ Fluxb2t 3 = TransferCoeﬀbloodtissue× (Cvs - Cextra 3/Ptissue2blood)
Cvs = Ablood 3 u7/ Vbloodspleen
d(Aextracellular 3 u8)
d푡
=Diﬀ Fluxb2t 3 - Carrier Mediated 3 - Diﬀ Fluxe2i 3
- Active Transp 3 - Spleen Phagocytosis2 (57)
where
Diﬀ Fluxb2t 3 = TransferCoeﬀbloodtissue× (Cvs - Cextra 3/Ptissue2blood)
Carrier Mediated 3 = Vmaxe2i× Cextra 3/(Kme2i + Cextra 3)
- Vmaxi2e× (Cintra 3/Pintra2extra)/(Kmi2e + Cintra 3/Pintra2extra)
Diﬀ Fluxe2i 3 = TransferCoeﬀextra2intra× (Cextra 3
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- Cintra 3/Pintra2extra)
Active Transp 3 = Vmaxe2i× Cextra 3 / (Kme2i + Cextra 3)
Spleen Phagocytosis2 = Aextracellular 3 u8× Phagocytosis Coeﬀ
Cextra 3 = Aextracellular 3 u8/ Vextraspleen
Cintra 3 = Aintracellular 3 u9 / Vintraspleen
d(Aintracellular 3 u9)
d푡
=Carrier Mediated 3 + Diﬀ Fluxe2i 3 + Active Transp 3
(58)
where
Carrier Mediated 3 = Vmaxe2i× Cextra 3/(Kme2i + Cextra 3)
- Vmaxi2e×(Cintra 3/Pintra2extra)/(Kmi2e + Cintra 3/Pintra2extra)
Diﬀ Fluxe2i 3 = TransferCoeﬀextra2intra× (Cextra 3 - Cintra 3/Pintra2extra)
Active Transp 3 = Vmaxe2i× Cextra 3 / (Kme2i + Cextra 3)
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(b) Brain expanded
Figure 72. Brain IE and expanded models in STELLA R⃝
Brain IE.
d(Abrain u10)
d푡
=Arterial to Brain - Brain to Venous (59)
where
Arterial to Brain =Qbrain× Ca× BBB Factor
Brain to Venous =Qbrain× Cvbrain
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Cbraintissue1 =Abrain u10 / Vbrain
Cvbrain =Cbraintissue1 / P
Brain (Expanded).
d(Ablood 4 u10)
d푡
=From Arterial 4 - To Venous 4 - Diﬀ Fluxb2t 4 (60)
where
From Arterial 4 =BBB Factor×Qbrain× Ca
To Venous 4 =Qbrain× Cvb
Diﬀ Fluxb2t 4 =TransferCoeﬀbloodtissue× (Cvb - Cextra 4/Ptissue2blood)
Cvb =Ablood 4 u10/ Vbloodbrain
d(Aextracellular 4 u11)
d푡
=Diﬀ Fluxb2t 4 - Carrier Mediated 4
- Diﬀ Fluxe2i 4 - Active Transp 4 (61)
where
Diﬀ Fluxb2t 4 =TransferCoeﬀbloodtissue× (Cvb - Cextra 4/Ptissue2blood)
Carrier Mediated 4 =(Vmaxe2i× Cextra 4/(Kme2i + Cextra 4)
- Vmaxi2e×(Cintra 4/Pintra2extra)/(Kmi2e + Cintra 4/Pintra2extra)
Diﬀ Fluxe2i 4 =TransferCoeﬀextra2intra× (Cextra 4 - Cintra 4/Pintra2extra)
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Active Transp 4 =Vmaxe2i× Cextra 4 / (Kme2i + Cextra 4)
Cextra 4 =Aextracellular 4 u11/ Vextrabrain
Cintra 4 =Aintracellular 4 u12 / Vintrabrain
d(Aintracellular 4 u12)
d푡
=Carrier Mediated 4 + Diﬀ Fluxe2i 4 + Active Transp 4
(62)
where
Carrier Mediated 4 =(Vmaxe2i× Cextra 4/(Kme2i + Cextra 4)
- Vmaxi2e×(Cintra 4/Pintra2extra)/(Kmi2e + Cintra 4/Pintra2extra)
Diﬀ Fluxe2i 4 =TransferCoeﬀextra2intra× (Cextra 4 - Cintra 4/Pintra2extra)
Active Transp 4 =Vmaxe2i× Cextra 4 / (Kme2i + Cextra 4)
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(b) RPT expanded
Figure 73. RPT IE and expanded models in STELLA R⃝
RPT IE.
d(Arpt u13)
d푡
=Arterial to RPT - RPT to Venous (63)
where
Arterial to RPT =Qrpt× Ca
RPT to Venous =Qrpt× Cvrpt
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Crpt =Arpt u13 / Vrpt
Cvrpt =Crpt / P
RPT (Expanded).
d(Ablood 5 u13)
d푡
=From Arterial 5 - To Venous 5 - Diﬀ Fluxb2t 5 (64)
where
From Arterial 5 =Qrpt× Ca
To Venous 5 =Qrpt× Cvrpt2
Diﬀ Fluxb2t 5 =TransferCoeﬀbloodtissue× (Cvrpt2 - Cextra 5/Ptissue2blood)
Cvrpt2 =Ablood 5 u13/ Vbloodrpt
d(Aextracellular 5 u21)
d푡
=Diﬀ Fluxb2t 5 - Carrier Mediated 5
- Diﬀ Fluxe2i 5 - Active Transp 5 (65)
where
Diﬀ Fluxb2t 5 =TransferCoeﬀbloodtissue× (Cvrpt2 - Cextra 5/Ptissue2blood)
Carrier Mediated 5 =Vmaxe2i× Cextra 5/(Kme2i + Cextra 5)
- Vmaxi2e×(Cintra 5/Pintra2extra)/(Kmi2e + Cintra 5/Pintra2extra)
Diﬀ Fluxe2i 5 =TransferCoeﬀextra2intra× (Cextra 5 - Cintra 5/Pintra2extra)
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Active Transp 5 =Vmaxe2i× Cextra 5 / (Kme2i + Cextra 5)
Cextra 5 =Aextracellular 5 u21/ Vextrarpt
Cintra 5 =Aintracellular 5 u22 / Vintrarpt
d(Aintracellular 5 u22)
d푡
=Carrier Mediated 5 + Diﬀ Fluxe2i 5 + Active Transp 5
(66)
where
Carrier Mediated 5 =Vmaxe2i× Cextra 5/(Kme2i + Cextra 5)
- Vmaxi2e×(Cintra 5/Pintra2extra)/(Kmi2e + Cintra 5/Pintra2extra)
Diﬀ Fluxe2i 5 =TransferCoeﬀextra2intra× (Cextra 5 - Cintra 5/Pintra2extra)
Active Transp 5 =Vmaxe2i× Cextra 5 / (Kme2i + Cextra 5)
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(b) SPT expanded
Figure 74. SPT IE and expanded models in STELLA R⃝
SPT IE.
d(Aspt u14)
d푡
=Arterial to SPT - SPT to Venous (67)
where
Arterial to SPT =Qspt× Ca
SPT to Venous =Qspt× Cvspt
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Cspt =Aspt u14 / Vspt
Cvspt =Cspt / P
SPT (Expanded).
d(Ablood 6 u14)
d푡
=From Arterial 6 - To Venous 6 - Diﬀ Fluxb2t 6 (68)
where
From Arterial 6 =Qspt× Ca
To Venous 6 =Qspt× Cvspt2
Diﬀ Fluxb2t 6 =TransferCoeﬀbloodtissue× (Cvspt2 - Cextra 6/Ptissue2blood)
Cvspt2 =Ablood 6 u14/ Vbloodrpt
d(Aextracellular 6 u23)
d푡
=Diﬀ Fluxb2t 6 - Carrie Mediated 6
- Diﬀ Fluxe2i 6 - Active Transp 6 (69)
where
Diﬀ Fluxb2t 6 =TransferCoeﬀbloodtissue× (Cvspt2 - Cextra 6/Ptissue2blood)
Carrier Mediated 6 =Vmaxe2i× Cextra 6/(Kme2i + Cextra 6)
- Vmaxi2e×(Cintra 6/Pintra2extra)/(Kmi2e + Cintra 6/Pintra2extra)
Diﬀ Fluxe2i 6 =TransferCoeﬀextra2intra× (Cextra 6 - Cintra 6/Pintra2extra)
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Active Transp 6 =Vmaxe2i× Cextra 6 / (Kme2i + Cextra 6)
Cextra 6 =Aextracellular 6 u23/ Vextraspt
Cintra 6 =Aintracellular 6 u24 / Vintraspt
d(Aintracellular 6 u24)
d푡
=Carrier Mediated 6 + Diﬀ Fluxe2i 6 + Active Transp 6
(70)
where
Carrier Mediated 6 =Vmaxe2i× Cextra 6/(Kme2i + Cextra 6)
- Vmaxi2e×(Cintra 6/Pintra2extra)/(Kmi2e + Cintra 6/Pintra2extra)
Diﬀ Fluxe2i 6 =TransferCoeﬀextra2intra× (Cextra 6 - Cintra 6/Pintra2extra)
Active Transp 6 =Vmaxe2i× Cextra 6 / (Kme2i + Cextra 6)
156
Venous Blood Calculation
To maintain mass balance, we assume
∑푛
푖=1 푄푖 = 푄푐, where 푄푐 is cardiac output.
Concentration in mixed venous blood, 퐶푣, is taken as the weighted average of the
concentrations from each organ.
Cv =[(Qportal+Qliver)× Cvliver + Qkidney× Cvkidney
+ Qbrain× Cvbrain + Qrpt× Cvrpt + Qspt× Cvspt]/Qc (71)
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Appendix D. Matrix Formats for MATLAB R⃝ Model
This appendix describes the matrix formats for the baseline model created in
Phase I Model Formulation in Section 3.1 on page 33. To assemble the A-matrix
in MATLAB R⃝, we use A=Input1+Input2-Output+Exchange-Loss, where Input1 ac-
counts for inputs into all organs except the lungs and Input2 is for lungs only. This
was done to better organize the coding in MATLAB R⃝. Note that Input1, Input2, and
Output remain the same, regardless of the transport process that is used (instanta-
neous equilibration, diﬀusion, active transport, or carrier mediated transport). Loss
and Exchange may change, depending on the transport assumptions.
Throughout the MATLAB R⃝ code, variables ‘a’, ‘b’, ‘c’, and ‘d’ were used to
represent groupings of coeﬃcients. Descriptions of these variables is as follows:
∙ a=fraction of nanoparticles exiting each compartment (output)
∙ b=fraction of total blood ﬂow to each compartment (input)
∙ c=fraction exchanged between two compartments (exchange)
∙ d=fraction excreted or otherwise lost from a compartment (loss)
The MATLAB R⃝ code is built around a 24×24 matrix format, with each row repre-
senting the ODE for a speciﬁc subcompartment (e.g., liver blood, liver extracellular,
etc.). An index showing the row positions is shown in Figure 75 on the following
page.
Below are the matrices for Input1, Input2, and Output. Input1 accounts for inputs
into all organs except the lungs and Input2 is for lungs only.
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1.  liverblood
2.  liverextracellular
3.  liverintracellular
4.  kidneyblood
5.  kidneyextracellular
6.  kidneyintracellular
7.  spleenblood
8.  spleenextracellular
9.  spleenintracellular
10. brainblood
11. brainextracellular
12. brainintracellular
13.  rptblood
14. sptblood
15. mucosa
16. alveolarair
17. alveolarsurface
18. alveolarblood
19. giblood
20. gilumen
21. rptextracellular
22. rptintracellular
23. sptextracellular
24. sptintracellular
Figure 75. Index for the 24 rows
Input1 =
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎣
푏1
0
0
0.8⋅푏2
0
0
푏3
0
0
0.1⋅푏4
0
0
푏5
푏6
0
0
0
0
푏8
0
0
0
0
0
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎦
[ 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 푎7 0 0 0 0 0 0 ]
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=⎡⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎣
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 푏1푎7 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.8⋅푏2푎7 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 푏3푎7 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.1⋅푏4푎7 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 푏5푎7 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 푏6푎7 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 푏8푎7 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎦
(72)
Input2 =
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎣
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎦
[ 푎1 0 0 푎2 0 0 0 0 0 푎4 0 0 푎5 푎6 0 0 0 0 0 0 0 0 0 0 ]
=
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎣
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
푎1 0 0 푎2 0 0 0 0 0 푎4 0 0 푎5 푎6 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎦
(73)
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Output =
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎣
푎1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 푎2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 푎4 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 푎5 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 푎6 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎦
(74)
4.0.0.2 Loss.
The Loss matrix is diagonal, as loss terms are written as ﬁrst-order losses. See
Equation 75.
LossIE =
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎣
d1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 d3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 푑71 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 푑72 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 푑8 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎦
(75)
The Loss matrix is diﬀerent for IE vs. Diﬀusion/Active/Carrier Mediated as the
loss mechanisms are more accurately placed at the subcompartment level for the
latter three processes, as compared to IE which only has a single compartment. For
Diﬀusion/Active/Carrier Mediated transport processes, note that in Equation 76 on
the following page the losses 푑1 and 푑3 are in diﬀerent locations, as they now leave
from the extracellular subcompartment:
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Loss =
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎣
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 d1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 d3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 푑71 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 푑72 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 푑8 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎦
(76)
4.0.0.3 Exchange.
The Exchange matrix will diﬀer depending on whether an assumption of IE, dif-
fusion, active transport, or carrier mediated transport is assumed for each organ. As
would be assumed based on its name, the exchange matrix terms always occur in
pairs (vertically). For example, 푐16 is subtracted from row 1 and is added to row 20,
which represents the “exchange” of nanoparticles between the liver and GI tract. The
Exchange matrix for IE, in terms of coeﬃcients c, is:
ExchIE =
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎣
−푐16 0 0 0 0 0 푐36 0 0 0 0 0 0 0 0 0 0 0 푐82 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 −푐36 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 −푐71 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 −푐72 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 푐72 −푐73푎 푐73푏 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 푐73푎 −푐73푏 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 −푐81푎−푐82 푐81푏 0 0 0 0
푐16 0 0 0 0 0 0 0 0 0 0 0 0 0 푐71 0 0 0 푐81푎 −푐81푏 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎦
(77)
For the other transport processes, each organ is represented with three subcompartments
instead of the single compartment. Exchanges between subcompartments are noted
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with coeﬃcients 푐푥. The three lines between the extracellular and intracellular sub-
compartments represent diﬀusion, active transport, and carrier mediated transport.
For this research, we leave all three transport processes on simultaneously (i.e., pro-
cesses operate in parallel). In the liver subcompartment, note also that 푐17 represents
the bile exchange for these transport processes, whereas 푐16 applies for the IE case
only.
(a) Liver Subcompartment (b) Kidney Subcompartment
(c) Spleen Subcompartment (d) Brain Subcompartment
Figure 76. Liver, kidney, spleen, and brain subcompartments
For diﬀusion between extra- and intracellular, we can write the submatrices for
the organs as follows:
ExchangeLiverdiﬀ =
[ −푐1푎 푐1푏 0
푐1푎 −푐1푏−푐17−푐12푎 푐12푏
0 푐12푎 −푐12푏
]
ExchangeKidneydiﬀ =
[ −푐2푎 푐2푏 0
푐2푎 −푐2푏−푐22푎 푐22푏
0 푐22푎 −푐22푏
]
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ExchangeSpleendiﬀ =
[ −푐36−푐3푎 푐3푏 0
푐3푎 −푐3푏−푐32푎 푐32푏
0 푐32푎 −푐32푏
]
ExchangeBraindiﬀ =
[ −푐4푎 푐4푏 0
푐4푎 −푐4푏−푐42푎 푐42푏
0 푐42푎 −푐42푏
]
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⎡ ⎢ ⎢ ⎢ ⎢ ⎢ ⎢ ⎢ ⎢ ⎢ ⎢ ⎢ ⎢ ⎢ ⎢ ⎢ ⎢ ⎢ ⎢ ⎢ ⎢ ⎣−푐 1
푎
푐 1
푏
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
푐 1
푎
−푐
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1
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⎤ ⎥ ⎥ ⎥ ⎥ ⎥ ⎥ ⎥ ⎥ ⎥ ⎥ ⎥ ⎥ ⎥ ⎥ ⎥ ⎥ ⎥ ⎥ ⎥ ⎥ ⎦
(7
8)
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Matrix formats for active transport and carrier mediated transport are assembled
in a similar manner. One diﬀerence, however, is how to deal with the nonlinear terms
associated with the Michaelis-Menten kinetics equation. If the system of ODEs is
solved with those nonlinear terms as is, the major diﬀerence is that exchanges be-
tween extracellular and intracellular are no longer linear functions of concentration
and the exchange terms need to be added outside of the A-matrix. In other words,
the linear relationship A⋅⃗푐 no longer applies. Alternatively, the nonlinear terms can
be linearized, such as by using a ﬁrst- or zero-order assumption as discussed in Sec-
tion 4.1.3 on page 103. Any resulting ﬁrst-order terms would be included in the
A-matrix and zero order terms would be added outside the A-matrix.
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Appendix E. Eigenvalue Analysis Background
Derivation of the Steady State Solution
In this appendix, the solution to the linear system of diﬀerential equations shown
in Equation 79 is determined.
˙⃗푐 = 퐴푐⃗+ 푠⃗(푡),where 푐⃗(0) = 푐⃗표 (79)
The solution method will use the properties of eigenvalues and their associated
normalized eigenvectors. To this end, we assume there is a complete set of linearly
independent eigenvectors {푣⃗푖}푛푖=1 associated with eigenvalues {휆⃗푖}푛푖=1 for matrix 퐴,
such that
퐴푣⃗푖 = 휆푖푣⃗푖, 푖 = 1, 2, . . . , 푛 (80)
The eigenvectors are chosen so that 푣⃗ 푇푖 푣⃗푖=1 (i.e., the transpose of the eigenvector
applied on the eigenvector=1). Next, we deﬁne the matrix of eigenvectors, 퐸, as:
퐸 =
[
푣⃗1 푣⃗2 ⋅ ⋅ ⋅ 푣⃗푛
]
(81)
From this we observe
퐴퐸 =
[
퐴푣⃗1 퐴푣⃗2 ⋅ ⋅ ⋅ 퐴푣⃗푛
]
(82a)
=
[
휆1푣⃗1 휆2푣⃗2 ⋅ ⋅ ⋅ 휆푛푣⃗푛
]
= 퐸Λ (82b)
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where
Λ =
⎡⎢⎢⎢⎢⎣
휆1
휆2
. . .
휆푛
⎤⎥⎥⎥⎥⎦ (83)
is the diagonal matrix of eigenvalues. Because the eigenvectors are linearly indepen-
dent, 퐸−1 exists and it follows that
퐴 = 퐸Λ퐸−1 (84)
Returning to the solution of Equation 79 on the preceding page, we introduce the
coordinate transformation
푐⃗(푡) = 퐸푦⃗(푡) (85)
This leads to
˙⃗푐 = 퐸 ˙⃗푦 = 퐴퐸푦⃗ + 푠⃗(푡), 푐⃗(0) = 퐸푦⃗(0) = 푐⃗표 (86)
Then by using Equation 84 we have
˙⃗푦 = Λ푦⃗ + 퐸−1푠⃗(푡), 푦⃗(0) = 퐸−1푐⃗표 (87)
This equation is now an uncoupled system of equations; that is, we may simply
write it as
푦˙푘(푡) = 휆푘푦푘(푡) + 푓푘(푡), 푦푘(0) = 푏푘 푘 = 1, 2, . . . , 푛 (88)
where 푓푘(t)=(퐸
−1푠⃗)푘, the 푘th element of the vector 퐸−1푠⃗(t) and 푏푘=(퐸−1푐⃗표)푘. This
equation has the solution
푦⃗(푡) = 푒휆푘푡푏푘 +
∫ 푡
0
푒휆푘(푡−휏)푓푘(휏)d휏. (89)
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Thus, the solution to Equation 87 becomes
푦푘(푡) = 푒
Λ푡퐸−1푐⃗표 +
∫ 푡
0
푒Λ(푡−휏)퐸−1푠⃗(휏)d휏. (90)
Applying Equation 85 produces the desired solution
푐⃗(푡) = 퐸푒Λ푡퐸−1푐⃗표 +
∫ 푡
0
퐸푒Λ(푡−휏)퐸−1푠⃗(휏)d휏. (91)
or
푐⃗(푡) =
푛∑
푘=1
푣⃗푘푦푘(푡) (92a)
=
푛∑
푘=1
푏푘푣⃗푘푒
휆푘푡 +
푛∑
푘=1
푣⃗푘
∫ 푡
0
푒휆푘(푡−휏)푓푘(휏)d휏. (92b)
Next, we examine the solution in the context of this research, which focuses on
concentration. First, assume the source vector 푠⃗(t) is constant, then 푓푘 is constant
and the integral in Equation 92b can be evaluated to produce the solution
푐⃗(푡) =
푛∑
푘=1
푏푘푣⃗푘푒
휆푘푡 +
푛∑
푘=1
푓푘
휆푘
(
푒휆푘푡 − 1) 푣⃗푘. (93)
The ﬁrst sum represents the evolution due to the initial concentration 푐⃗표, while the
second sum represents the evolution due to the constant source, 푠⃗. The evolution of
the concentration vector is clearly governed by the sign and size of the eigenvalues, 휆푘.
If 휆푘 is positive, we have exponential growth, while a negative 휆푘 produces exponential
decay. In the context of this research, however, all of the eigenvalues 휆 are negative.
Therefore, the ﬁrst summation term of Equation 93 decays away and is not a major
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contributor to long-term concentration. We can rewrite the equation as
푐⃗(푡) ≈
푛∑
푘=1
푓푘
휆푘
(
푒휆푘푡 − 1) 푣⃗푘 = 푛∑
푘=1
푓푘
−휆푘
(
1− 푒휆푘푡) 푣⃗푘. (94)
On the other hand, the second term in Equation 93 evolves into the steady state
concentration which can also be found by setting ˙⃗푐=0 in Equation 79 on page 167
and solving for 푐⃗ss (steady state), i.e.,
푐⃗ss = −퐴−1푠⃗ =
푛∑
푘=1
푓푘
−휆푘 푣⃗푘. (95)
It is convenient to choose 푣⃗푘 so that every component of 푓⃗ is positive. This can
be done by simply observing if -푓푘 <0 then 푓푘 >0 and 푓푘 ⋅ 푣푘 = (−푓푘)(−푣푘) so we
replace 푣푘 with -푣푘, if 푓푘 is negative.
A Steady State Example
For the kidney example ﬁrst described in Section 3.1.5.4 on page 55 and shown
again in Figure 77 on the next page, the mass balance diﬀerential equation is written
in general terms as shown in Equation 96a. The input, output, and exchange terms
can be combined to form the A-matrix as they are linear terms. However, the source
term is not linearly dependent and must be kept separate. Note that the source term
ﬂows into the kidney blood subcompartment.
푉
d
dt
⎡⎢⎢⎢⎢⎣
퐶푏
퐶푒
퐶푖
⎤⎥⎥⎥⎥⎦ = Input−Output + Exchange + Source (96a)
170
Kidney Blood
Extracellular
Urine
QkCaQkCv
Tb:t(Cb - Ce/Pt:b)
Qk= kidney blood flow rate, liters/hr
Ca = nanoparticle concentration in arterial blood, x1000 particles/liter
Cv = nanoparticle concentration in venous blood, x1000 particles/liter
Tb:t = blood-to-tissue diffusion transfer coefficient, liters/hr
Cb = nanoparticle concentration in kidney blood, x1000 particles/liter
Ce = nanoparticle concentration in extracellular, x1000 particles/liter
Pt:b = tissue-to-blood partition coefficient (unitless)
Te:i = extra-to-intracellular diffusion transfer coefficient, liters/hr
Ci = nanoparticle concentration in intracellular, x1000 particles/liter
Pt:b = tissue-to-blood partition coefficient (unitless)
Intracellular
Te:i(Ce - Ci/Pi:e)
Figure 77. Example used for eigenvalue analysis
⇒ d
dt
⎡⎢⎢⎢⎢⎣
퐶푏
퐶푒
퐶푖
⎤⎥⎥⎥⎥⎦ = ⋅ ⋅ ⋅ =
⎡⎢⎢⎢⎢⎣ 퐴
⎤⎥⎥⎥⎥⎦
⎡⎢⎢⎢⎢⎣
퐶푏
퐶푒
퐶푖
⎤⎥⎥⎥⎥⎦+
⎡⎢⎢⎢⎢⎣
푠
0
0
⎤⎥⎥⎥⎥⎦ (96b)
Using Equation 16 on page 56 and substituting in values for the parameters, the
A-matrix equals:
퐴 =
⎡⎢⎢⎢⎢⎣
−푇b:t − 0.2 ⋅푄푘
푉푏
푇b:t
푃t:b푉푏
0
푇b:t
푉푒
− 푇b:t푃t:b푉푒 −
푇e:i
푉푖
푇e:i
푃i:e푉푒
0 푇e:i푉푖
− 푇e:i푃i:e푉푖
⎤⎥⎥⎥⎥⎦ =
⎡⎢⎢⎢⎢⎣
−595.8 83.06 0
33.2 −23.26 2.2
0 8.31 −2.77
⎤⎥⎥⎥⎥⎦
(97)
Assuming an inhalation concentration of 퐶inh=500 (x1000 particles/liter) and
blood volume 푉푏= 0.0301 liters, the source vector can be written as shown in Equa-
tion 98. Note that the blood volume, 푉푏, appears in the denominator as the linear
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system is multiplied by 푉 −1 to clear volume from the left-hand side of the ODEs.
푠⃗ =
⎡⎢⎢⎢⎢⎣
퐶inh
푉푏
0
0
⎤⎥⎥⎥⎥⎦ =
⎡⎢⎢⎢⎢⎣
500
0.0301
0
0
⎤⎥⎥⎥⎥⎦ =
⎡⎢⎢⎢⎢⎣
16611
0
0
⎤⎥⎥⎥⎥⎦ (98)
Previously in Figure 16c on page 57, the eigenvalues were displayed using the
L1-norm, where the components are fractions which sum to one for each eigenvector.
Figure 78 displays the eigenstructure with eigenvectors written using the L2-norm
(i.e., sum of squares of the components equals one).
⎡⎢⎣ -600.6 -19.56 -1.682−0.9983 −0.1281 0.0181
0.0575 −0.8890 0.1297
−0.0008 0.4397 0.9914
⎤⎥⎦ (1)
1
Figure 78. Eigenstructure (using L2 norm)
Therefore, we have
퐸 =
⎡⎢⎢⎢⎢⎣
−0.9983 −0.1281 0.0181
0.0575 −0.8890 0.1297
−0.0008 0.4397 0.9914
⎤⎥⎥⎥⎥⎦⇒ 퐸−1 =
⎡⎢⎢⎢⎢⎣
−0.9934 0.1429 −0.0005
−0.0604 −1.0478 0.1382
0.0260 0.4648 0.9474
⎤⎥⎥⎥⎥⎦ (99)
The L2-norm of the eigenvectors can then be used to write the general solution to
the system of ODEs for this example. First, we solve for 푓⃗ by applying the inverse of
the eigenvector matrix, 퐸, onto the source vector, 푠⃗:
푓⃗ = 퐸−1 ⋅ 푠⃗ (100a)
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⇒ 푓⃗ =
⎡⎢⎢⎢⎢⎣
−0.9934 0.1429 −0.0005
−0.0604 −1.0478 0.1382
0.0260 0.4648 0.9474
⎤⎥⎥⎥⎥⎦
⎡⎢⎢⎢⎢⎣
16611
0
0
⎤⎥⎥⎥⎥⎦ =
⎡⎢⎢⎢⎢⎣
−16502
−1003
432
⎤⎥⎥⎥⎥⎦ (100b)
To make all terms in 푓⃗ positive, we multiply the corresponding eigenvector in the
E-matrix by ‘-1’. Since the ﬁrst two terms of 푓⃗ are negative, we multiply the ﬁrst two
eigenvectors (i.e., columns) of E by ‘-1’:
new푓⃗ =
⎡⎢⎢⎢⎢⎣
16502
1003
432
⎤⎥⎥⎥⎥⎦⇒ new퐸 =
⎡⎢⎢⎢⎢⎣
0.9934 −0.1429 −0.0005
0.0604 1.0478 0.1382
−0.0260 −0.4648 0.9474
⎤⎥⎥⎥⎥⎦ (101)
Equation 102 shows the concentration in the blood subcompartment as a function
of time, using the values for 푓푘, 휆푘, and 푣푘 and Equation 94 on page 170.
퐶푏(푡) =
푓1
−휆1
(
1− 푒휆1푡) (푣⃗11) + 푓2−휆2 (1− 푒휆2푡) (푣⃗21) + 푓3−휆3 (1− 푒휆3푡) (푣⃗31)
=
16502
600.6
(
1− 푒−600.6푡) (0.9983) + 1003
19.56
(
1− 푒−19.56푡) (0.1281)
+
432
1.682
(
1− 푒−1.682푡) (0.0181) (102)
Once solved, the concentration equations for the blood subcompartment is as
shown in Equation 103a. Equations for the extracellular and intracellular subcom-
partments are shown in Equations 103b and 103c, respectively.
퐶푏(푡) = 27.43
(
1− 푒−600.6푡)+ 6.57 (1− 푒−19.56푡)+ 4.65 (1− 푒−1.682푡) (103a)
퐶푒(푡) = −1.58
(
1− 푒−600.6푡)+ 45.6 (1− 푒−19.56푡)+ 33.3 (1− 푒−1.682푡) (103b)
퐶푖(푡) = 0.022
(
1− 푒−600.6푡)− 22.55 (1− 푒−19.56푡)+ 254.5 (1− 푒−1.682푡) (103c)
Each concentration equation (Equations 103a - 103c) has three terms, with each
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one corresponding to a speciﬁc eigenvalue. Figure 79 shows the total concentration
plots (black lines) alongside plots for the three contributing components in each sub-
compartment. We note that both extracellular and intracellular have terms that
provide negative contribution to total concentration, as shown by plots extending
into the negative y-direction. These negative terms are also indicated by the negative
coeﬃcients in Equations 103a - 103c.
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Figure 79. Contributions of exponential terms and total concentration in kidney sub-
compartments
Figure 80 shows a comparison of the subcompartment concentrations shown in
Figure 79. Note that the slight s-shaped pattern for intracellular (red line) in Figure
80 indicates the eﬀect of a negative contribution term, which slows down the evolution
of concentration at low t. At higher t, the eﬀect of this term is more diﬃcult to discern
visually.
By recognizing that the exponential terms →0 as t→ ∞, we see that the con-
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Figure 80. Comparison of subcompartments
centrations are approximately equal to the sum of the coeﬃcients in Equations 103a
- 103c, which yields 퐶푏(t)≈38.65, 퐶푒(t)≈77.32, and 퐶푖(t)≈231.97. Alternatively, we
can estimate these steady state concentrations by using Equation 95 on page 170 or
by looking at the concentration values on the right side of the plots in Figure 79 on
the previous page.
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Appendix F. Eigenstructure Matrices
⎛⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎝
1. 푒푖푔푒푛푣푎푙푢푒
2. 푙푖푣푒푟푏푙표표푑
3. 푙푖푣푒푟푒푥푡푟푎푐푒푙푙푢푙푎푟
4. 푙푖푣푒푟푖푛푡푟푎푐푒푙푙푢푙푎푟
5. 푘푖푑푛푒푦푏푙표표푑
6. 푘푖푑푛푒푦푒푥푡푟푎푐푒푙푙푢푙푎푟
7. 푘푖푑푛푒푦푖푛푡푟푎푐푒푙푙푢푙푎푟
8. 푠푝푙푒푒푛푏푙표표푑
9. 푠푝푙푒푒푛푒푥푡푟푎푐푒푙푙푢푙푎푟
10. 푠푝푙푒푒푛푖푛푡푟푎푐푒푙푙푢푙푎푟
11. 푏푟푎푖푛푏푙표표푑
12. 푏푟푎푖푛푒푥푡푟푎푐푒푙푙푢푙푎푟
13. 푏푟푎푖푛푖푛푡푟푎푐푒푙푙푢푙푎푟
14. 푟푝푡푏푙표표푑
15. 푠푝푡푏푙표표푑
16. 푚푢푐표푠푎
17. 푎푙푣푒표푙푎푟푎푖푟
18. 푎푙푣푒표푙푎푟푠푢푟푓푎푐푒
19. 푎푙푣푒표푙푎푟푏푙표표푑
20. 푔푖푏푙표표푑
21. 푔푖푙푢푚푒푛
22. 푟푝푡푒푥푡푟푎푐푒푙푙푢푙푎푟
23. 푟푝푡푖푛푡푟푎푐푒푙푙푢푙푎푟
24. 푠푝푡푒푥푡푟푎푐푒푙푙푢푙푎푟
25. 푠푝푡푖푛푡푟푎푐푒푙푙푢푙푎푟
⎞⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎠
Figure 81. Index showing which subcompartments correspond to which rows
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